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ABSTRACT 
DEVELOPMENT OF MACROMOLECULAR PRODRUG CONJUGATES FOR 
THE TREATMENT OF INFLAMMATORY DISEASES 
 
 Inflammation is the complex biological response to the stimuli triggered by var-
ious factors like pathogens, damaged cells, or irritants.  Constant uncontrolled 
acute inflammation may become chronic conditions, leading to significant tissue 
damage, contributing to a series of chronic inflammatory diseases. Our lab has 
been working on the different types of inflammatory diseases and has developed 
multiple macromolecular prodrug conjugates for the better therapeutic efficacy and 
reduced toxicity. The general approach we have taken is to incorporate small mol-
ecules containing monomers into water-soluble and biocompatible polymers, such 
as N-(2-Hydroxypropyl) methacrylamide (HPMA) copolymers.  The superior and 
the sustained efficacy of those macromolecular prodrug may due to their Extrava-
sation through Leaky Vasculature and subsequent Inflammatory cell-mediated Se-
questration (ELVIS mechanism) at the inflammatory site.  To extend of our prodrug 
application, in my research, (1) we investigated whether the prodrug copolymer 
system we designed could ameliorate injury-induced inflammation.  We estab-
lished traumatic brain injury model in mice by the controlled cortical impact. We 
successfully ameliorated the neuroinflammation caused by the traumatic brain in-
jury using HPMA Dexamethasone copolymer conjugates. We also reduced the 
complication caused by traumatic brain injury such as systemic osteopenia. (2) We 
xii 
 
utilized HPMA Tofacitinib copolymer conjugates (P-Tofa) to ameliorate the inflam-
mation at the colon in a mouse ulcerative colitis model. We proved its improved 
therapeutic efficacy by targeting and retaining at the colon tissue. (3) To further 
reduce the toxicity of systemic administrated therapeutic agents while increasing 
the targeting property, we designed a local drug delivery system named Local Ex-
tracorporeal Vascular Circuit (LEVC).  We minimized the systemic exposure of the 
drug and achieved superior local accumulation of the drug in ischemia-reperfusion 
injury mouse model. Collectively, the results from these systematic studies provide 
us the insight of the wider application of these prodrugs in the treatment of inflam-
matory diseases.   
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CHAPTER 1. INTRODUCTION 
1.1 Inflammation 
Inflammation is the complex biological response to against the stimuli triggered 
by various factors like pathogens, damaged cells, or irritants.  Constant uncon-
trolled acute inflammation may become chronic conditions, leading to significant 
tissue damage, contributing to a series of chronic inflammatory diseases.  Inflam-
mation could also be initiated by diseases affecting the immune system within the 
organism.  Abnormal inflammatory responses are associated with many autoim-
mune diseases such as rheumatoid arthritis, inflammatory bowel disease, and sys-
temic lupus erythematosus.  The responses of tissue to those injuries include 
inflammatory reactions related to both innate and adaptive immune system. [1]  
Traumatic injury induces inflammation which is a complex biological process with 
effects on host defense and would healing.  An important regulator of inflammation 
is cytokine which plays a central role in the initiation, regulation, and attenuation of 
inflammatory responses. [2]  After injury, the edema formed at the site of injury due 
to vascular leakage and white blood cells recruited to the injury site. This process 
will benefit the wound healing; however, if the injury happens to the brain or spinal 
cord, the swelling might cause further injury to the tissue and result in further neu-
ron degeneration. [3]  Inflammation covers a wide range of diseases, most of which 
are chronic and cause a big financial burden for the nation. More than 100 diseases 
are categorized as the autoimmune disease. [4]  More than 23 million Americans 
suffer from autoimmune disease associating with high societal costs. [5]  In this 
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chapter, we will provide an overview of several inflammatory diseases including 
autoimmune diseases and injury induced inflammatory condition such like trau-
matic brain injury and ischemia-reperfusion injury. 
1.1.1 Rheumatoid Arthritis 
 Rheumatoid arthritis (RA) is an autoimmune and inflammatory disease which 
affects 1 percent of adults in the United States. [6, 7]  In RA patients, the immune 
system mistakenly attacks healthy tissue and causes painful inflammation. RA 
mainly attacks the joint but can affect other organs such as the heart and lung.  
Cartilage damage and peri-articular bone erosion in RA patients would be painful 
and result in the loss of mobility.  At present, there is no cure for RA. [8, 9]   
 Many drugs have been developed to treat RA including nonsteroidal anti-in-
flammatory drugs (NSAIDs), glucocorticoids (GCs) and disease-modifying anti-
rheumatic drugs (DMARDs).  NSAIDs, including ibuprofen, naproxen sodium, and 
aspirin, have been shown to ease pain and inflammation associated with RA. [10, 
11]  However, NSAIDs cannot prevent joint damage and are often associated with 
significant gastrointestinal, renal [12] and cardiovascular [13] side effects.  In the 
past decades, GCs have been widely used in the treatment of RA patients. [12]  
Their long-term use, however, has been associated with serious side effects in-
cluding bone loss with an increased incidence of fractures, infections, diabetes 
mellitus, hypertension, and cardiovascular complication. [14, 15]  DMARDs, such 
as hydroxychloroquine, leflunomide, sulfasalazine and methotrexate (MTX) are 
currently being utilized to control disease progression and inhibit joint inflammation. 
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[16]  By selectively targeting proinflammatory cytokines or immunomodulatory 
pathways, DMARDs have been shown to be effective in ameliorating joint destruc-
tion and suppressing joint inflammation. [17]  After discovering the JAK/STAT (Ja-
nus Kinase/Signal Transducer and Activator of Transcription) pathway in 
rheumatoid arthritis, JAK inhibitors have been developed which selectively target 
individual members of the Janus kinase pathway. [18]  Several small molecule JAK 
inhibitors have been approved by Food and Drug Administration (FDA), which offer 
new hope to RA patients who have experienced severe side effects or are refrac-
tory to current the treatments. [19]   
1.1.2 Inflammatory bowel disease 
 Inflammatory bowel disease (IBD) includes two conditions which are Crohn’s 
Disease (CD) and Ulcerative colitis (UC). In 2015, there are approximately 1.3% 
of US adults reported being diagnosed with IBD. [20]  CD can affect any part of the 
gastrointestinal tract most commonly in the small intestine. [21]  There are 3.1 to 
14.6 cases diagnosed as Crohn’s disease per 100,000 persons each year. [22]  
UC resulting in a chronic and relapsing inflammatory response in the colon, affect-
ing approximately 1 million Americans, resulting in substantial disability. [23-26]  
Approximately 38,000 new cases of UC per year are reported in the United States, 
[26]  with the related annual direct or indirect costs estimated to be $8.1-14.9 billion. 
[27]  The current treatment of IBD includes anti-inflammatory agents (e.g., gluco-
corticoids and 5-aminosalicylates) and immunosuppressants (e.g., tumor necrosis 
factor (TNF) inhibitors and anti-integrin antibodies). [28, 29]  Clinical use of these 
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medications for moderate to severe UC, however, only result in sustained remis-
sion in less than 30% of the time.  Around 20 to 30% of patients with UC eventually 
would need colectomy, which is a complex procedure with complications. [30]  Cur-
rently, there is no cure for UC, and there is an urgent need for a new therapy to 
augment the natural progression of the disease.  
1.1.3 Traumatic Brain Injury 
 Traumatic brain injury (TBI) is a serious public health concern which affects 
over 2 million people each year in the United States. [31]  TBI is not only affecting 
a large population across the nation but also contributes to 30% death of all injury-
related deaths. [32]  TBI is caused by a bump, blow, jolt or penetrating head injury 
to the head that disrupts the normal function of the brain. [33]  Another major cause 
of TBI is explosive blast injury among soldiers in the military. [34]  Besides focal 
brain damage due to contact injury types resulting in contusion, laceration, and 
intracranial hemorrhage, diffuse brain injury due to acceleration/deceleration 
would also result in diffuse axonal injury or brain swelling. [35-38]  The leading 
cause of TBI is falling which account for 47% of TBI related emergency department 
visits, hospitalization, and death in the United States in 2013. [32]  Most of the TBI 
(79%) in aged adults over 65 years old are caused by falls. [32]  The second lead-
ing cause of TBI is the head striking or being struck by an object which accounts 
15% TBI related emergency department visits, hospitalizations and death in the 
United States in 2013. [32, 39]  The third leading cause of TBI related emergency 
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department visits, hospitalization, and death in the United States in 2013 is motor 
vehicle crashes which account for 14%. [32]   
 There are two injury stages following traumatic brain injury which are primary 
injury and secondary injury.  The primary injury happens at the time of injury which 
the damage is direct to the brain tissue resulting in local neuron death. [40]  Differ-
ent region in the brain may show different sensitivity to the mechanical force be-
cause of the different tissue deformation threshold. [41]  Secondary injury is the 
indirect result of the traumatic injury. It starts several hours to several days after 
primary injury and can cause long term injury. The severity and development of 
secondary injury contribute to the death of TBI incidence. [42]  A large percentile 
survived from the trauma at the time of injury and died days to weeks after due to 
secondary injury. [43]  With the development of the secondary injury, the neurons 
not damaged in primary injury may be lethalafter the triggering a sequence of 
events lead to cerebral edema, cerebral ischemia, increased cranial pressure, and 
neurodegeneration. [44-46]  Cerebral inflammation and inflammation associated 
edema are important pathological mechanisms initiated by TBI. The formation of 
cerebral edema has been associated with a greater risk of death during hospitali-
zation [47] and is associated with poor outcomes even in mild-to-moderate injuries. 
[48]  Cerebral edema is the major cause of brain swelling that can lead to increased 
intracranial pressure (ICP) [49] which is also a significant predictor of morbidity and 
mortality following an injury. [50]  The cause of cerebral edema has both cytotoxic 
and vasogenic origins. [51]  Cytotoxic edema leads to increased intracellular water 
content resulting from a failure of ATP-dependent Na+/K+ pumps.  This process 
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produces an imbalance in the cellular ion content and metabolic disturbances. [51, 
52]  Vasogenic edema results from a disruption of the blood-brain barrier (BBB) 
causing water to shift from the vasculature to the parenchyma along an osmotic 
gradient resulting in brain swelling and increased ICP. [51, 52]   
 The prevention or amelioration of secondary injury becomes more and more 
important in the treatment of TBI.  If the secondary injury and the degeneration 
process could be attenuated, the outcome and survival rate would be dramatically 
changed.  So more and more studies and therapeutic interventions focused on the 
relief of secondary injury. [53]  As discussed above, inflammation and inflammation 
associated edema plays an important role in the progress of secondary injury.  
Successful prevention of the inflammation after brain injury may attenuate the 
damage caused by secondary injury.   
1.1.4 Ischemia-Reperfusion Injury 
 Ischemia occurs when the blood flow is restricted to an area of tissue where 
the nutrient and oxygen cannot be delivered to the tissue and metabolite in the 
tissue cannot be transported out.  After the restoration of the blood flow, the intro-
duction of oxygen species will damage the tissue and cause more free radicals 
released from the tissue and further damaging the tissue.  Rather than restore the 
normal function, reperfusion causes more injuries to the tissue.  Ischemia-
reperfusion can happen at any organ in the body. The most common ischemia in 
the body is myocardial ischemia-reperfusion injury, kidney ischemia-reperfusion 
injury, hepatic ischemia-reperfusion injury and ischemic stroke in the brain. [54-58]  
7 
 
Besides the ischemia-reperfusion injury in the organs, tourniquet-induced 
ischemia-reperfusion injury is also a big concern. [59]  Tourniquet has been widely 
used in first-line treatment of severe limb hemorrhage. [60-63]  Hemorrhage from 
extremity injuries is the most common cause of preventable death in civilian and 
battlefield. [64, 65]  Based on the Center for Disease Control and Prevention report 
in 2010, over 14 million emergency department visits and $80 billion cost is related 
to extremity injuries every year. [66]  The use of tourniquet successfully treated the 
injured leg and prevented death. The tourniquet is also widely used in vascular 
and orthopedic surgeries to create an optimal bloodless operating field. [67, 68]  
However, by restricting and restoration of the blood flow, tourniquet induces seri-
ous acute ischemia-reperfusion injury in the skeletal muscle and neuromuscular 
junction.  Excessive inflammatory cytokines and reactive oxygen species in injured 
skeletal muscles during the acute ischemia-reperfusion causes neuronal damage 
and deficit of skeletal muscle function. [69-72]  By inhibiting the production and 
release of inflammatory cytokines is one of the strategies to treat limb ischemia-
reperfusion injury. 
1.1.5 Systemic Lupus Erythematosus (SLE)  
 Systemic lupus erythematosus (SLE), the most common type of lupus, is an 
autoimmune disease in which the immune system attacks its own tissues, causing 
widespread inflammation, producing autoantibodies and tissue damage in the af-
fected organs. SLE can affect the joints (lupus arthritis), skin (cutaneous lupus), 
brain (neuropsychiatric SLE), lungs (Lupus Pneumonitis), kidneys (lupus nephritis), 
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and blood vessels (Vasculitis). It has been reported that in the United States, the 
prevalence of systemic lupus erythematosus is 20 to 150 cases per 100,000. [73, 
74]  Women has higher prevalence rates from 164 (white) to 406 (African American) 
per 100,000. [75]   
 Lupus nephritis is one of the most damaging diseases of systemic lupus ery-
thematosus.  It is the leading cause of morbidity and mortality among lupus pa-
tients. Around 35% adult systemic lupus erythematosus patients in the U.S. have 
been diagnosed lupus nephritis at the time of diagnosis.  An additional 15−25% 
patients will develop nephritis within 10 years of their initial diagnosis. [76]  Lupus 
nephritis is initiated by abnormal immune complex deposition on the basement 
membrane of glomeruli and the subsequent activation of the immune effector cells 
(e.g., macrophages and neutrophils), leading to damage of the renal tissues. [77]  
Lupus nephritis can develop rapidly to impair renal function and eventually result 
in kidney failure. [78]  Among the limited treatment options, [79]  long term gluco-
corticoid (GC) is one of the most potent and widely used to control immune re-
sponses. To date, there is no cure for lupus nephritis. Development of novel drug 
or drug delivery system targeting kidney with reduced systemic side effects be-
come more and more important. 
1.2 Novel Nanomedicine for Treatment of Inflammatory Diseases 
 Different from conventional pharmaceutical product, nanomedicine is a prom-
ising approach to offer targeted, sustained and controlled release of drugs at the 
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inflammatory site.  To formulate nanomedicine, we shall understand the nature of 
the nanomedicine and the factors which will also influence the nanomedicine itself.  
 The structure of nanomedicine can vary due to different types of payload [80]. 
While micelles, dendrimers, liposomes, nanoparticles and polymer-drug 
conjugates all share the concept of macromolecular therapeutics, they can be very 
different in their structures [81]. Different delivery systems are also applied to 
deliver different candidates because of their unique properties. Formulations of 
nanomedicine shall be established on the understanding of the nature of the 
nanomedicine and the factors influenced the nanomedicine itself.  Here, we will 
discuss about different types of the nanomedicines and their applications. 
1.2.1 Liposomes 
 Liposomes have been used as a drug delivery vesicle since the 1960s [82]. 
Liposomes are composed by phospholipid membrane which is a double layer with 
fluidity surrounded by the aqueous environment.  The shape of the liposomes is 
basically spherical. Liposomes can be categorized into multilamellar vesicle (MLV) 
[83], a small unilamellar vesicle (SUV) [84] and large unilamellar vesicle (LUV) [85] 
according to the number of lipid layers and the size of liposomes.  Most of the 
clinically used liposomal formulations have been decorated with inert water-soluble 
polymers (e.g., PEG, HPMA copolymer, etc.) to ensure their stealth property 
against the mononuclear phagocyte system (MPS), which will extend the half-life.  
The surface decorating polymers can also be used to introduce various targeting 
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moieties or imaging probes.  Liposome size can vary from 100 to 400 nm in diam-
eter and plays a critical role in complement activation and MPS clearance of the 
delivery system [86, 87]. Vesicles larger than 100 nm require additional strategies 
to prevent surface opsonization. [88]  The first FDA approved liposomes, liposo-
mal-doxorubicin (also called Doxil or Lipodox or Myocet), was approved to use on 
the treatment of several cancer diseases including the treatment of soft tissue sar-
comas [89-91]. 
1.2.2 Nanoparticles 
 Nanoparticles can be categorized as drug nanoparticles, solid nanoparticles, 
polymer-based nanoparticles, lipid-based nanoparticles, and nanocapsules. Drug 
nanoparticles are the dispersion of water-insoluble drug particles of drug formula-
tions in the nanosized range in an aqueous environment. Drug nanoparticles can 
be achieved by breaking down the bigger particles by high-pressure homogeniza-
tion method or by special crystallization techniques. Polymer-based nanoparticles 
are commonly composed of poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly 
(lactic acid-co-glycolic acid) (PLGA), poly(-caprolactone) (PCL), and poly(methyl-
methacrylate) (PMMA). Chemical synthesis, salting-out, emulsification-diffusion, 
nanoprecipitation, and freeze-drying methods are used to obtain polymer-based 
nanoparticles. Lipid-based nanoparticles mostly composed of fats or waxes and 
can be obtained by homogenization. For certain applications, nanoparticles may 
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be tailored into different shape: namely sphere nanoparticles [92], cube nanopar-
ticles [93], rod-like nanoparticles [94], hollow spherical nanoparticles [95] and ran-
dom shape nanoparticles.  
1.2.3 Dendrimers 
 Dendrimers are highly uniformed, branched or star-shaped macromolecules. 
Dendrimers can be synthesized by divergent [96] or convergent approaches [97].  
They are often of uniform molecular weight and very low polydispersities.  Den-
drimers also have a modifiable surface functional group as well as internal cavities 
[98].  For example, Newkome et al. [99] have synthesized a dendrimer containing 
hydrophobic interior and hydrophilic surface functionality.  During or after the 
synthesis of dendrimers, the drug molecules can be physically entrapped or chem-
ically conjugated to the dendrimer [100].   
1.2.4 Micelles  
Micelles are self-assembled colloidal systems containing amphiphilic mole-
cules, which can spontaneously aggregate to from micelles at a concentration 
higher than the critical micelle concentration (CMC).  The size and the shape of 
the micelle can vary from 10 nm to over 100 nm, spherical [101], ellipsoid cylin-
dered, worm-like or monolayer micelle. [102]  A typical micelle has hydrophilic tails 
forming a shell structure, and the inner hydrophobic structure can encapsulate or 
conjugate with poorly water-soluble drugs.  This structure can be achieved using 
three types of macromolecular drugs: 1. The molecule is composed of the one 
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polar end (hydrophilic group) and one non-polar end (hydrophobic group) [103]. 2. 
Two polar ends with the non-polar center [101]. 3. Two non-polar ends with the 
polar center [104].  To improve micelle stability, Liu et al. prepared poly (2-cin-
namoylethyl methacrylate-b-acrylic acid) which forms polymeric micelles in water 
[105, 106] and cross-linked the core segment by photochemically induced 
polymerization of the cinnamoyl side groups which decreases the free volume of 
the core. The core density may increase, and the size of the micelles might de-
crease because of the crosslinking.  
1.2.5 Macromolecular conjugates 
 A macromolecular prodrug or polymeric-drug conjugates consist of a polymeric 
backbone, active drugs, targeting moiety, and imaging moiety.  The primary struc-
ture of the conjugates and the chemical bonds by which the components are linked 
to the backbone can be designed base on the conjugates applications [107], drug 
properties [108, 109] and biological rationales. [110-112]  The shape of HPMA-
copolymer conjugates [113], the length of the backbone [113], the number of the 
side chain and the length of the side chain [114] can be managed to some degree 
by different synthetic strategies.  Reversible addition-fragmentation chain transfer 
(RAFT) polymerization is commonly used to manage the molecular weight and 
polydispersity of the polymer conjugates which will affect the distribution, accumu-
lation and the elimination of the conjugates on a living organism. [81, 115]  The 
macromolecular conjugates have a hydrodynamic diameter of less than 10 nm 
[116] may result in much fewer MPS uptake and provide a better-controlled drug 
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releasing profile by optimizing the covalent bond or linker between the drug and 
the carrier backbone.   
In our lab, we have developed and tested an HPMA copolymer based dexame-
thasone copolymer to detect and treat early signs of wear particle-induced peri-
implant granulomatous inflammation with minimal “off-target” side effects. [117, 
118]  This system is based upon our discovery that macromolecular theranostic 
agents can specifically target to sites of inflammation and undergo uptake and ac-
tivation by inflammatory cells [117, 119].  Besides HPMA conjugated macromolec-
ular polymer drug, the PEGylated drug conjugates have also shown its promise in 
the drug delivery system to treat lupus nephritis. [120, 121]   
 We have tested our prodrug on several inflammatory diseases such as rheu-
matoid arthritis [122] and lupus nephritis [119].  The great challenge for the devel-
opment of the nanomedicine to target inflammatory diseases also remains a great 
opportunity for the researchers to develop smarter and safer drug delivery systems.   
1.3 Targeting strategies 
 The targeting of the polymeric conjugates to the pathologic site is essential for 
drug delivery. Researchers have made tremendous efforts to modify the delivery 
system to obtain a better targeting property to further enhance the therapeutic 
efficacy and reduce the off-target systemic toxicity.  The drug targeting mecha-
nisms are generally categorized into active targeting and passive targeting. [123]   
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1.3.1 Active targeting 
 Active targeting is using the target moiety, such as antibody and specific low 
molecular weight ligands, to direct the payload to preferentially accumulate to the 
site of pathology. Active targeting always takes advantages of the different patho-
logical features of the lesion when compared to the normal tissue. The preferential 
interaction of the antigen expressed on the cell surface of a particular disease le-
sion and the targeting moiety of the delivery system will facilitate the active target-
ing process. As one may speculate, this strategy can lower the side effect of the 
drug by reducing unnecessary drug exposure to normal tissues. 
1.3.1.1 Antibody-mediated targeting 
Conjugate bound with specific antibodies is called antibody-targeted polymer 
conjugates. While such conjugation would significantly improve the polymer-drug 
conjugates’ diseases targeting ability, the original antigen binding affinity of the 
antibodies conjugated to polymeric drug carriers can be compromised due to the 
chemical modification process. [124]  Recently, a new method has been developed, 
attempting to address this problem. [125]  A heterodimeric coiled-coil structure can 
be formed with a highly specific interaction between peptide K ((VAALKEK)4) and 
peptide E ((VAALEKE)4).  Benefiting from such molecular recognition, a cytostatic 
drug-bearing HPMA copolymer peptide E conjugate was synthesized, and self-
assembled with peptide K tagged BCL1 leukemia cells specific scFv of B1 mAb, 
to obtain an antibody-polymer drug conjugate with largely intact antibody targeting 
ability.  
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1.3.1.2 Folate-mediated targeting  
Folate shows high affinity to its receptors, folate binding proteins.  This unique 
property has established folate as a popular active targeting moiety to assist the 
intracellular transportation and drug/drug delivery systems. [126, 127]  The folate 
receptors are highly expressed on the cancer cells [128], which would facilitate the 
active targeting of folate bearing polymer conjugates to the cancer lesion.  The 
conjugates can be transported intracellularly via receptor-mediated endocytosis.  
Unlike liposomes, micelles, and nanoparticles, the hydrophobicity of folate affects 
polymer-drug conjugate more because it can be hidden within the polymer random 
coil but not on the surface like in the other nanomedicine formulations.  To over-
come this limitation, researchers introduced positive charges into the HPMA co-
polymer conjugates. [129]  Folate receptor (FR) positive Hela cells were used to 
test the drug-cell binding affinity.  In the presence of folate-modified cationic HPMA 
copolymers, FR antibody bounded cells decreased from 71.2% to only 34.0%.  
This indicates that the positive charge could probably amplify the binding efficiency 
of folate to its receptor due to the close proximity of conjugates to the cell surface 
by the electronic adhesion.  To avoid non-specific binding by a positive charge in 
the circulation, the researchers applied the charge shielding/deshielding approach. 
Charge shielding groups 2,3-dimethyl maleic anhydride (DMA) can be specifically 
hydrolyzed at tumor extracellular environment (pH 6.8).  Then the conjugates show 
the charge-reversible ability, leading to the faster endocytosis into the cells of can-
cerous lesion than the normal tissue (pH 7.4).  This technique may improve the 
folate-mediate targeting of HPMA copolymer conjugates to cancer. 
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1.3.1.3 Transferrin mediated targeting 
Similar to folate, transferrin is another well-studied targeting moiety because of the 
overexpression of its receptor on the cancer cells surface [130] and brain micro-
vascular endothelial cells. [131]  The binding of transferrin with its receptor would 
lead to its endocytosis.  Iron in plasma will bind with transferrin and dissociate from 
it in the acidic compartment in the cell.  Copolymers consist of the hydrophobic 
monomer lauryl methacrylate (LMA), a reactive anhydride functional methacrylate, 
and a large polyethylene glycol methacrylate monomer was copolymerized and 
conjugated to transferrin.  This docetaxel-containing, transferrin receptor-targeting 
conjugate shows the enhanced cancer cell killing properties in vitro cytotoxicity 
studies. [132] 
1.3.2 Passive targeting 
 In 1979, the antitumor protein drug neocarzinostatin (NCS) was conjugated 
with a synthetic copolymer of styrene-maleic acid copolymer (SMA) which was 
called SMANCS (molecular weight 16,000 g/mol) by Maeda. [133]  This antitumor 
protein-drug conjugate exhibited many unique properties, including prolonged half-
life in circulation (20-fold), improved tumor-targeting capacity (2000 folds intra-tu-
mor concentration than plasma), no immunogenicity and higher lipophilicity. [134-
136]  These properties led to the conceptualization of the Enhanced Permeability 
and Retention effect (EPR effect). [137]  With the advantage of the EPR effect, 
SMANCS became the first macromolecular anticancer drug approved in 1993 in 
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Japan. [134]  The EPR effect has been observed in the applications of many na-
nomedicine formulations, such as polymer conjugates, polymeric micelles, and lip-
osomes. [138, 139]  Most HPMA copolymers utilize the EPR effect to achieve 
better tumor targeting and delivery of drugs.  EPR effect is a tumor vasculature-
dependent phenomenon.   Most tumors are well vascularized with high density, 
and the rapid growth of blood vessels leads to irregular vascular alignment and 
defects of the junction between endothelial cells.  The increased local fenestration 
of macromolecules paired with the ill-developed lymphatic drainage at the tumor 
lesion leads to the local accumulation of macromolecules over time. [134, 140-144]  
Wang et al. first described macromolecules’ Extravasation through Leaky Vascu-
lature and their subsequent Inflammatory cell-mediated Sequestration (ELVIS). 
[145]  It explains the passive targeting of the HPMA copolymer–dexamethasone 
conjugate (P-Dex) to inflammations. [146, 147]  Unlike the traditional 
understanding of EPR effect that macromolecules only can passively target to solid 
tumors (not inflammation) due to the leaky vasculature and impaired lymphatic 
drainage, they found although the extravasated macromolecules are cleared from 
the inflammatory tissue quickly, rapid internalization by inflammatory infiltrates, 
and locally activated cells provide the mechanism for the sustained retention of the 
macromolecular drug conjugate at the site of inflammation. 
 In the following chapters, we will introduce our work on the development of 
macromolecular prodrug conjugates for the treatment of inflammatory diseases. 
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CHAPTER 2. Aquaporin-4 expression is inversely correlated with brain stiff-
ness following controlled cortical impact in mice 
 
2.1 Introduction 
As discussed in chapter 1, the secondary injury of traumatic brain injury plays 
an important role in the survival of patients after injury.  More deaths are related to 
severer secondary injury and edema is the key factor of secondary injury.  Diag-
nosis of edema after mild traumatic brain injury becomes more and more important 
to evaluate and treat traumatic brain injury clinically.  It has been shown that mi-
croscopic magnetic resonance elastography (µMRE) detected brain stiffness 
change after traumatic brain injury in a preclinical study. [148]  In this chapter, we 
want to find the evidence that the stiffness change observed in µMRE correlates 
to brain edema after brain injury.   
Cerebral edema is an important pathological mechanism initiated by traumatic 
brain injury (TBI).  The formation of cerebral edema has been associated with a 
greater risk of death during hospitalization [47] and is associated with poor out-
comes even in mild-to-moderate injuries. [48]  Cerebral edema is the major cause 
of brain swelling that can lead to increased intracranial pressure (ICP) [49] which 
is also a significant predictor of morbidity and mortality following an injury. [50] 
The cause of cerebral edema has both cytotoxic and vasogenic origins. [51]   
Cytotoxic edema leads to increased intracellular water content resulting from a 
failure of ATP-dependent Na+/K+ pumps.  This process produces an imbalance in 
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the cellular ion content and metabolic disturbances. [51, 52]  Vasogenic edema 
results from a disruption of the blood-brain barrier (BBB) causing water to shift from 
the vasculature to the parenchyma along an osmotic gradient resulting in brain 
swelling and increased ICP. [51, 52]  
One of the central mediators of both cytotoxic and vasogenic edema is aqua-
porin 4 (AQP4).  AQP4 is one of 14 proteins in the aquaporin family and is widely 
expressed in the astrocyte cell plasma membrane, but it is primarily localized to 
specific regions on the cell, such as the perivascular astrocyte endfeet [149, 150] 
in the vicinity of cerebral blood vessels. [151]  AQP4-deficient mice have improved 
outcomes following acute water intoxication, a model of cerebral edema that 
causes increased swelling of the astrocytic endfoot processes while leaving the 
BBB intact. [152]  AQP4 deletion reduces astrocyte water permeability and atten-
uates brain swelling after TBI. [153]  In models where edema is predominately 
vasogenic in nature, AQP4-deficient mice have worse outcomes suggesting a role 
in the resolution of vasogenic edema. [149, 154]  Recent studies have identified 
an AQP4 polarity shift from the astrocyte endfoot processes to the soma following 
injury [155, 156], though the significance of this shift is not known.  
Previous studies have shown that cerebral edema can alter the mechanical 
properties of the brain.  For example, cryogenic lesioning of the cat brain produced 
vasogenic edema as evidenced increased water content at 4 and 24 hours after 
injury, which corresponded to a decrease in tissue elasticity measured by ex vivo 
indentation methods. [148]  The same investigators also reported a similar finding 
in Mongolian gerbils at 24 hours following cerebral ischemia. [157]  In this paper 
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[158], the author reported edematous regions of the lung are less elastic, and the 
edema can be quantified by MRE (magnetic resonance elastography).  Recently, 
our group has developed a method for noninvasive, quantitative measurement of 
brain stiffness following traumatic injury. [159]  Using microscopic magnetic reso-
nance elastography (µMRE), we monitored adult male mice over an extended pe-
riod following different severities of trauma.  We demonstrated decreased stiffness 
at the lesion epicenter was significantly lower than the rest of the brain that lasted 
through seven days post-injury.  This time frame is generally accepted as the time 
when the damaged cerebral vasculature is most permeable and allows for the pas-
sage of water and serum proteins to the parenchyma. [160, 161]  
The purpose of the current study is to correlate changes in AQP4 expression 
with regions of decreased brain stiffness following CCI.  We hypothesize that post-
traumatic decreases in brain stiffness will occur in regions of AQP4 translocation 
on the astrocyte.  To test this hypothesis, we will determine AQP4 colocalization 
with the astrocyte marker glial acidic fibrillary protein (GFAP), in regions of de-
creased tissue stiffness following TBI.  Additionally, we will determine the expres-
sion of other members of the AQP family along with regulators of the neurovascular 
unit.  The results of these studies will help develop µMRE as a diagnostic modality 
and lead to therapy development by providing a mechanistic explanation for non-
invasive neuroimaging results. 
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2.2 Methods 
2.2.1 Animal handling 
This study utilized 32 C57BL/6 adult male mice (Charles River Laboratories, 
Wilmington, MA).  The animals were housed in individual cages in a climate-con-
trolled room and kept on a 12 h light/dark cycle.  Continual access to food and 
water was provided throughout the study.  All procedures and protocols were 
approved by the Institutional Animal Care and Use Committee of the University of 
Nebraska Medical Center and conducted following the National Institutes of Health 
Guide for the Care and Use of Laboratory.  
All mice were 5-7 weeks old at the start of the study.  The mice were selected 
at random to be exposed to CCI injury or left as naive, as previously described. 
[159]  Following the induction of anesthesia with 5% inhaled isoflurane, the heads 
of the mice were shaved and positioned in a Kopf stereotaxic head frame (David 
Kopf Instruments, Tujunga, CA).  Anesthesia was maintained with 2% inhaled 
isoflurane, which was delivered through a nose cone.  A midline incision was 
completed, and a 4 mm craniotomy was performed lateral to the midline and mid-
way between bregma and lambda to expose the underlying somatosensory cortex, 
taking care not to disturb the dura.  The head frame was then positioned beneath 
a Precision Systems and Instrumentation TBI-0310 (Fairfax Station, VA) that ad-
ministered a 0.75 mm cortical compression (3 mm impactor diameter, 3.5 m/sec 
velocity, 500 msec dwell time).  Following injury, Surgicel (Johnson & Johnson, 
Dallas, TX) was placed over the injury site.  Next, the skull cap was put back in 
place and sealed using dental acrylic.  The skin incision was closed with EZ clip 
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wound closures (Stoelting CO., Illinois), and the incision was infused with 0.5% 
bupivacaine with 1:200000 epinephrine as topical analgesia.  Following closure, 
the animals were placed in their home cage and sacrificed on 1 hour, 24 hours, 7 
days post-injury. Control animals were left intact (naïve) and sacrificed on 7 days.  
Every time point has 8 mice, 4 for immunohistochemistry and 4 for real-time re-
verse transcription-polymerase chain reaction (real-time RT-PCR). 
For immunohistochemistry group, the mice were deeply anesthetized and per-
fused transcardially with 0.1M phosphate buffered saline (PBS) followed by 4% 
paraformaldehyde in PBS.  The mice were decapitated, and the brain was 
harvested in 30% sucrose in PBS.  Brain tissues were dehydrated in sucrose over-
night and flash frozen in 2-Methylbutane (Fisher Scientific) on dry ice.  Brains were 
cryostat sectioned at 20 µm thickness, and every other section was collected.  For 
real-time RT-PCR, mice were decapitated immediately after euthanasia and brain 
were dissected.  Lesion area of ipsilateral cortex and the same area of symmetrical 
contralateral cortex were harvested and froze in liquid nitrogen. 
2.2.2 RNA extraction and cDNA synthesis 
Samples were homogenized in 1.5 ml Trizol (Life Technologies) using a mortar 
plus liquid nitrogen and RNA was extracted according to the single-step acid-phe-
nol-guanidinium method. [162]  The RNA samples were reverse transcribed into 
cDNA using oligo (dT)-selection according to the manufacture’s protocol (Reverse 
Transcription kit, Qiagen).  A 300 ng total RNA sample was used for the single 
strand cDNA synthesis.  The reverse transcription reaction was incubated at 42°C 
for 30 mins and terminated at 95°C for 3 min. 
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2.2.3 Real-time reverse transcription-polymerase chain reaction (real-time RT-
PCR) 
Aquaporin 4 (AQP 4), aquaporin 9 (AQP 9), claudin-5, occludin, tight junction 
protein 1 (ZO-1), and tight junction protein 2 (ZO-2) transcript level were quantified 
using Fast SYBR® Green Master Mix (Life Technologies, Carlsbad, CA) and the 
ABI Prism 7000 real-time PCR system (Applied Biosystems, Carlsbad, CA).  After 
a 10 min denaturation step at 95°C, cDNA was amplified by performing two-step 
PCR cycles: a 3 s step at 95°C, followed by a 15 s step at 60°C.  The transcript 
data were normalized to the housekeeping gene, glyceraldehydes-3-phosphate-
dehydrogenase (GAPDH).  Reactions were performed in triplicate.  The primer 
sequences of tested genes are listed below in Table 2.1.  Expression of target 
genes was normalized to GAPDH and expressed as the fold ratio relative to the 
control group, using the 2-ΔΔCT method. [163] 
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Gene Primer Sequences 
GAPDH 5’- CTTTGTCAAGCTCATTTCCTGG -3’ 
 5’- TCTTGCTCAGTGTCCTTGC-3’ 
ZO-1 5’-AGCTCATAGTTCAACACAGCCTCCAG-3’ 
 5’-TTCTTCCACAGCTGAAGGACTCACAG-3’ 
ZO-2 5’- GGAGACCAGATTCTGAAGGTGAACAC-3’ 
 5’- 
ACCTTTGGGGATTTCTAGCAGGTAGAGGAC-
3’ 
AQP4 5’-GCTTTCTGGAAGGCAGTCTCA-3’ 
 5’- GGCTACAGTCACAGCGGGA-3’ 
AQP9 5’-CCTTCTGAGAAGGACCGAGCC-3’ 
 5’- CTTGAACCACTCCATCCTTCC-3’ 
Claudin-
5 
5’-CACGGGAGGAGCGCTTTAC-3’ 
 5’- GGCACCGTCGGATCATAGAACT-3’ 
Occludin 5’-ATGTCCGGCCGATGCTCTC-3’ 
 5’- TTTGGCTGCTCTTGGGTCTGTAT -3’ 
 
Table 2.1 Primer sequences of gene expression quantified by real-time RT-PCR  
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2.2.4 Immunohistochemistry 
Five sections from the center of lesion area were selected for each injured brain, 
and the same area sections were selected for each control brain.  Sections were 
incubated with Image-iT® FX Signal Enhancer (Life Technologies, Grand Island, 
NY) to eliminate the non-specific background.  Sections were blocked with 10% 
normal donkey serum in TBST (Tris-Buffered Saline with 0.05% Tween 20, pH 7.6) 
with 0.25% Triton-X added, incubated with polyclonal anti-Aquaporin 4 antibody 
(1:100) (ab46182, Abcam, Cambridge, MA) and polyclonal anti-GFAP antibody 
(1:1000) (ab53554, Abcam, Cambridge, MA) for 16 hours at 4˚C.  Then sections 
were incubated with Alexa Fluor® 488 Donkey Anti-Rabbit IgG antibody (1:1000) 
and Alexa Fluor® 546 Donkey Anti-Goat IgG antibody (1:1000) (Life Technologies, 
Grand Island, NY) in the dark at room temperature for one hour.  Slides were 
mounted with Prolong® Gold Antifade Reagent with DAPI (Life Technologies, 
Grand Island, NY) and dried overnight at room temperature. 
2.2.5 Confocal Laser Scanning Microscope 
AQP4/GFAP double-labeled sections were imaged using a Zeiss 710 Confocal 
Laser Scanning Microscope with 40x oil and 63x oil objectives.  Zeiss software 
was used to acquire z-stack images with a Z step of 1 µm.  Imaging fields were 
randomly selected from the lesion cortex area and symmetrical contralateral cortex 
area.  Thus, 10 images were collected from one animal, and 160 total images were 
analyzed using image-pro plus software.  Imaging parameters (laser power, pho-
tomultiplier tube voltage, and gain) were held constant throughout all imaging ses-
sions.  All images were set to a consistent background compared to control group 
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images.  For the following image analysis steps, the person conducting the analy-
sis was blinded to the experimental group.  To measure AQP4 and GFAP 
expression immunoreactivity, the emission channels were split, and the images 
were converted to gray 8-bit images, and then the signal intensity was calculated. 
To measure APQ4 and GFAP co-localization, Pearson’s Correlation Coefficient 
was calculated by image-pro plus software. 
2.2.6 Statistical Analysis 
All values are expressed as mean ± standard deviation.  Data were statistically 
evaluated and plotted in the Prism software (GraphPad, La Jolla, CA, USA).  
Comparisons between groups over time were made by two-way ANOVA with 
Tukey’s test.  For all statistical tests, a p-value ≤ 0.05 was considered significant.  
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
2.3 Results 
2.3.1 Increased AQP4 and GFAP immunoreactivity after injury 
After the injury, astrocytes were activated and edema mediator AQP4 was 
highly expressed.  To confirm the increasing expression of AQP4 and astrocytes 
bio marker GFAP within 7 days after injury while the µMRE stiffness is decreasing, 
we calculated the AQP4 (Figure 2.1A) and GFAP (Figure 2.1B) expression of dif-
ferent time point.  Based on the 2-way ANOVA test, the ipsilateral cortex of 7 days 
post-injury has a significant increase of AQP4 expression comparing to 1 hour 
(p<0.05) and naïve (p<0.05).  The GFAP expression of 7 days ipsilateral cortex 
also has a significant increase compared to Naïve, 1 hour and 24 hours (p<0.05). 
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As expected, the AQP4 and GFAP expressed over 5 times compared to the control 
group on the ipsilateral cortex.  Figure 2.2 shows the location of AQP4 and GFAP 
which was assessed by confocal laser scanning microscope at 400x magnification.  
On the contralateral side, AQP4 and GFAP were rarely expressed within 7 days 
after injury.  On the ipsilateral side, AQP4 and GFAP expression significantly in-
creased.  After the injury, the immunoreactivity of AQP4 and GFAP increase sig-
nificantly within the lesion area, where the µMRE stiffness decreased. 
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Figure 2.1 Ipsilateral cortex shows an increasing expression of AQP4 and GFAP 
after injury.  A.  AQP4 expression increases significantly after injury within 7 days 
comparing to 1 hour (p<0.05) and naïve (p<0.05).  B.  GFAP expression after injury 
also has a significant increase.  GFAP expression on ipsilateral cortex 7 days after 
injury has a significant increase compared to Naïve, 1 hour and 24 hours (p<0.05). 
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2.3.2 Increased co-localization of AQP4 and GFAP  
To further confirm the hypothesis that the µMRE stiffness decreasing happens 
at the region of edema, we use the astrocyte biomarker GFAP as a label to see 
the translocation of AQP4 on astrocyte.  In Figure 2.2, 7 days after the injury, the 
astrocytes were highly activated, and aquaporin 4 also had a high expression.  The 
yellow part is the overlay of red and green which means the co-localization of aq-
uaporin 4 and GFAP.  Comparing the ipsilateral hemisphere of naïve, 1h after 
injury and 7 days after injury, the aquaporin 4 location is changed.  In the beginning, 
the aquaporin 4 is located at the endfeet of astrocyte, and it shows a big molecule.  
In 7 days after injury, the aquaporin 4 were turned to be small molecules and mi-
grate to the soma of astrocytes.  The aquaporin 4 were spread all-over the astro-
cytes and reducing the edema formed by TBI.  Figure 2.3 was achieved by confocal 
scanning microscope with 630x magnification.  AQP4 and GFAP were expressed 
increasingly with time post-injury increases.  At 1 hour post-injury, the AQP4 was 
still located at the end feet of an astrocyte.  At 7 days after injury, AQP4 was dis-
tributed all over the astrocyte and colocalized with GFAP.  In Figure 2.4, the bar 
chart shows the AQP4 and GFAP colocalization coefficient which proves the ex-
pression of aquaporin 4 is on the membrane of activated astrocytes.  Based on 2-
way ANOVA, the colocalization coefficient of 7 days post-injury increased signifi-
cantly compared to naïve ipsilateral side (p<0.05).  In the naïve or contralateral 
hemisphere, the astrocytes were barely activated and no significant increase of 
aquaporin 4 expressions.   
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Figure 2.2 Translocation of AQP4 after injury. Localization of AQP4 was assessed 
by confocal laser scanning microscope at 400x magnification. AQP4 was labeled 
green (Alexa® 488) and GFAP was labelled red (Alexa® 546). On the contralateral 
side, AQP4 and GFAP were rarely expressed within 7 days after injury. On the 
ipsilateral side, AQP4 and GFAP expression significantly increased. At 7 days after 
injury, AQP4 and GFAP are co-localized and AQP4 translocates on astrocytes.  
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Figure 2.3 Increasingly expressed AQP4 and GFAP on the ipsilateral side.  Mag-
nification is 630x. AQP4 and GFAP expression are increasing with time increases.  
The co-localization shows the distribution of AQP4 on astrocyte. At 7 days after 
injury, AQP4 was distributed all over the astrocyte and colocalized.  
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Figure 2.4 Ipsilateral cortex shows an increasing colocalization of AQP4 and GFAP 
after injury.  The co-colocalization increases significantly after injury within 7 days 
comparing to Naive (p<0.05).  The contralateral side does not have a significant 
increase of AQP4 and GFAP colocalization.  
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2.3.3 Gene expression of APQ4, AQP9, Occludin, Claudin-5, ZO-1, and ZO-2 
Gene expression results from the lesion area in the cortex correspond to the 
findings in the immunohistochemistry.  In Figure 2.5, aquaporin 4 gene express 
significantly higher comparing to negative, 1 hour and 24 hours groups. Aquaporin 
9 gene express significantly lower at 24 hours comparing to negative, 1 hour and 
7 days.  There is no significant difference in the expression of occludin, tight junc-
tion protein 1 and tight junction protein 2 at each time points.  Claudin-5 gene ex-
pression at 7 days is significantly increased compared to the negative group. 
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Figure 2.5 AQP4 gene expression increased comparing to negative, 1 hour and 
24 hours groups.  AQP9 gene expresses significantly lower at 24 hours comparing 
to negative, 1 hour and 7 days.  No significant different expression of occludin, 
tight junction protein 1 and tight junction protein 2 between each time points.  Clau-
din-5 gene expression at 7 days is significantly increased compared to negative 
group. 
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2.4 Discussion 
Cerebral edema is a process of water molecules accumulated in brain cells and 
the extracellular space which causes a pathological increase in brain volume and 
contributes to the morbidity associated with Traumatic Brain Injury.  Decades ago, 
cerebral edema was first classified into two main categories which are vasogenic 
edema and cytotoxic edema (also known as cellular edema). [164]  Vasogenic 
edema results from the structure break down of the blood-brain barrier after trau-
matic brain injury.  The breakdown of endothelial cells in tight junction allows intra-
vascular proteins and fluid to penetrate extracellular space.  With the aid of novel 
MRI techniques and immunoreactivity of immunoglobulin G (IgG), the increase in 
BBB permeability seen in vasogenic edema follows a bimodal time course with 
peaks at 1 to 3 hours after injury. [165-168]  Cytotoxic edema is usually associated 
with ATP dependent sodium (Na+) / potassium (K+) membrane pumps failure.  It 
leads to a low extracellular and high intracellular Na+ concentration.  The water 
content within the intracellular compartment is increased in response to the os-
motic gradient.  The compensatory movement of the water through specialized 
channels down its osmotic gradient follows and results in cellular swelling.  How-
ever, the cell swelling itself does not increase brain volume.  
Although water can diffuse across most tissues in the body freely, its movement 
is highly regulated in the brain through a family of specialized transmembrane 
channels known as aquaporin (AQP).  The predominate AQPs of the central nerv-
ous system is AQP4 which is expressed at the basolateral membrane of ventricular 
38 
 
ependymal cells and astrocyte foot processes where it facilitates vascular-paren-
chyma water transport.  It is reported that the destruction of the BBB results in the 
upregulation of AQP4 [169] and AQP4 may play a beneficial role in the resolution 
of vasogenic edema in addition to its well-established role in cytotoxic edema 
which is detrimental. [170]  In the current study, AQP4 expression from immuno-
histochemistry shows significant higher compared to the contralateral cortex.  At 7 
days it is significantly higher compared to other time points.  The RT-PCR experi-
ment results reprove the expression trend of AQP4.  As the second most abundant 
AQPs in the brain, AQP9 plays an important role in regulating glycerol permeability. 
[171]  Previous studies showed upregulation of AQP9 in edematous tissue. [172]  
In Figure 2.5, the AQP9 increased at 7 days post injury which suggests AQP9 
upregulation may contribute to the edema formation.  However, the AQP9 de-
creased at 24 hours post-injury which also been reported in the previous study. 
[173]  Although the mechanism behind the regulation of AQP9 is still unclear,  the 
decrease of AQP9 gene expression at 24 hours post-injury may due to the dam-
aged to the BBB.  As the BBB recover after 1 day of injury, the expression of AQP9 
increased.  AQP4 and AQP9 might be therapeutic targets to solve the edema fol-
lowing traumatic brain injury.  
The increased reactivity of astrocyte in response to injury is termed astrogliosis. 
[174]  This response includes the changes in morphology, increased expression 
of the intermediate filament proteins, glial fibrillary acidic protein (GFAP) and vi-
mentin and secretion of inflammatory mediators. [175, 176]  Reactive astrocytes 
39 
 
can acquire a hypertrophic morphology after injury, involving the extension of pro-
cesses and swelling of cell bodies.  Astrogliosis has been defined in the context of 
both neuroprotection and neurodegeneration. [176, 177]  Activated astrocyte are 
capable of producing pro-inflammatory cytokines, chemokines, and MMP that de-
grade the extracellular matrix and cause further BBB disruption.  However, astro-
cytes are also capable of producing factors to support repair and regeneration after 
CNS damage after moderate TBI. [177]  Anti-GFAP antibody is currently widely 
used the biomarker to evaluate astrocyte activation. In the present study, GFAP 
expresses significantly higher comparing to contralateral cortex which means as-
trocytes are activated.  At 7 days, GFAP expression reaches highest folds com-
paring to negative group.  From the immunohistochemistry study, we can see 
AQP4 is translocated at astrocyte and highly colocalized with astrocyte which 
means edema formation. 
Magnetic Resonance Elastography used clinically shows decreased stiffness 
from patients with edema. [178, 179]  With these finding in our experiments, we 
can validate our hypothesis that post-traumatic decreases in brain stiffness will 
occur in regions of AQP4 translocation on the astrocyte.  This also correlates with 
the finding of stiffness decrease after TBI using µMRE imaging.  Thus, µMRE im-
aging is a promising tool using as a diagnostic modality and lead to therapy devel-
opment by providing a mechanistic explanation for non-invasive neuroimaging 
results. 
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CHAPTER 3. Macromolecular Dexamethasone Prodrug Ameliorates Neuroin-
flammation and Prevents Bone Loss Associated with Traumatic Brain Injury   
3.1 Introduction 
 As discussed in Chapter 2, edema formation correlates to the stiffness change 
observed by µMRE.  Edema is a key factor of secondary injury after traumatic brain 
injury.  The edema formation is mainly caused by inflammation induced by the 
traumatic brain injury. [180]  Resolution of inflammation after brain injury becomes 
more and more important in the management of TBI. The mechanism of TBI is still 
unknown, and there is no cure for TBI. The main focus in the treatment of TBI 
clinically is to ameliorate the symptoms and complications after TBI.  It has been 
reported that reduced bone mass was observed in TBI patients. [181]  There is 
21.4% TBI patients diagnosed with osteoporosis and 41.1% TBI patients diag-
nosed with osteopenia. [182]  This phenomenon was also validated in preclinical 
mouse and rat TBI models. [183, 184]  The TBI associated osteopenia not only 
affects the patients’ quality life but also can be life-threatening.  The combination 
of balance disorder and osteopenia will put the TBI patients at a higher risk of fall 
which may cause another TBI and bone fracture.  Neurologic injury from TBI is 
largely attributed to the deleterious effects of the direct mechanical impact as well 
as secondary injury, which will increase intracranial pressure, leading to ischemic 
injuries.  While glucocorticoids (GC) have been used extensively to treat TBI, the 
clinical outcome has been controversial. [185, 186]  This may due to the limited 
distribution to the brain and GC’s systemic side effect.  Based on our experience 
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of macromolecular dexamethasone prodrug conjugates and the evidence of its im-
proved therapeutic efficacy and safety profile, we proposed to use this macromo-
lecular dexamethasone prodrug (P-Dex) to treat TBI.   
3.2 Materials and Methods  
3.2.1 Materials 
N-(2-Hydroxypropyl) methacrylamide (HPMA), N-methacryloyl glycylglycyl hy-
drazinyl dexamethasone (MA-Dex), and S,S′-bis(α,α′-dimethyl-α″-acetic acid)-tri-
thiocarbonate (CTA, purity >97%) were prepared as reported previously. [187]  
Sephadex LH-20 resin and PD-10 columns were obtained from GE HealthCare 
(Piscataway, NJ).  IRDye 800CW NHS ester was purchased from LI-COR, Inc. 
(Lincoln, NE).   All other reagents and solvents were purchased from either Sigma-
Aldrich (St. Louis, MO) or Acros Organics (Morris Plains, NJ).  All compounds were 
reagent grade or higher and used without further purification. 
3.2.2 Instruments 
1H and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Var-
ian, Palo Alto, CA, USA).  ÄKTA Pure system (GE HealthCare, Chicago, IL, USA) 
equipped with UV detector and Superdex 200 increase column 10/300 GL, multi-
angle light scattering (MALS) detector (Wyatt, Santa Barbara, CA, USA) and 
differential refractive index (dRI) detector (Wyatt, Santa Barbara, CA, USA) were 
used to determine the copolymers’ weight average molecular weight (Mw) and 
number average molecular weight (Mn).  Drug content was analyzed on an Agilent 
1100 HPLC system (Santa Clara, CA, USA) with a Hypersil™ ODS C18 Column 
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(Thermo Scientific, Waltham, MA, USA).  Immuno-fluorescence labeled slides 
were analyzed using a ZEISS LSM 800 confocal microscope (Peabody, MA, USA).  
Live animals were imaged using the LI-COR® Pearl imaging system (Lincoln, NE, 
USA).  Isoflurane vaporizer (Midmark Corp, Dayton, OH) was used to anesthetize 
animals during live imaging analyses.  Precision Systems and Instrumentation TBI-
0310 (Fairfax Station, VA) was used to establish traumatic brain injury.  Static 
weight bearing was measured using an Incap incapacitance tester (Columbus In-
struments, Columbus, OH).  
3.2.3 Synthesis of the macromolecular prodrugs  
 The HPMA copolymer-dexamethasone conjugates were synthesized by a re-
versible addition−fragmentation chain transfer (RAFT) copolymerization as de-
scribed previously [188].  The synthesis scheme is showed in Figure 3.1 below.  
N-(2-Hydroxypropyl) methacrylamide (HPMA, 400 mg) and N-methacryloyl 
glycylglycyl hydrazinyl dexamethasone (MA-Dex, 116 mg) were dissolved in anhy-
drous methanol (3.7 mL) and then copolymerized under argon at 60 °C for 48 h 
with 2,2″-azobis(isobutyronitrile) (AIBN, 4.4 mg) as an initiator and S,S′-bis(α,α′-
dimethyl-α″-acetic acid) trithiocarbonate (CTA, 4.16 mg) as the RAFT agent.  The 
final product HPMA copolymer Dexamethasone conjugates (P-Dex) were obtained 
by lyophilization after the removal of the unreacted low molecular weight com-
pounds using LH-20 column and 25 kDa cutoff dialysis tube. 
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Figure 3.1 Synthesis of HPMA copolymer–Dex conjugate (P-Dex) via RAFT copol-
ymerization. 
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3.2.4 Synthesis of P-Dex-APMA 
 To introduce fluorescent labels to the P-Dex for biodistribution analysis, primary 
amine was introduced into P-Dex using the following procedure: HPMA (400 mg) 
and MA-Dex (117.3 mg) were dissolved in anhydrous methanol (3.7 mL), N-(3-
aminopropyl) methacrylamide hydrochloride (APMA, 5.4 mg), 2,2′-azobisisobu-
tyronitrile (AIBN, 4.4 mg) as initiator and S,S′-bis(α, α′-dimethyl-α″-acetic acid)-tri-
thiocarbonate (CTA, 4.2 mg) as the RAFT agent, placed in an ampule, and purged 
with argon and polymerized at 60 °C for 48 hr.  The resulting polymer was purified 
LH-20 column and then dialyzed against ddH2O in 25 kDa cutoff dialysis tube. 
3.2.5 The synthesis of P-Dex-IRDye 
 To monitor its distribution after systemic administration, P-Dex was labeled with 
IRDye® 800CW.  The labeling procedure is briefly described as follows: IRDye® 
800CW carboxylate (1 mg), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hy-
drochloride (EDC, 1.6 mg) and hydroxybenzotriazole (HOBt, 0.5 mg) were 
dissolved in N,N-dimethylformamide (DMF, 1 mL) in the dark at 21 C and stirred 
for 30 min.  DIPEA (7 mg) and P-Dex-APMA (50 mg) in DMF (1 mL) were added 
into the reaction mixture and then stirred overnight.  The reaction solution was 
dialyzed to remove DMF and low molecular weight reactants.  P-Dex-IRDye was 
then obtained via lyophilization. 
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3.2.6 P-Dex characterization 
3.2.6.1 Dexamethasone content in P-Dex polymer 
 Dexamethasone standard curve was generated by HPLC measurement.  Dex-
amethasone base was used as standard and dissolved in Methanol:H2O = 9:1 so-
lution as the sample injection solution. Several diluted solutions were prepared at 
the designed concentration as shown in the chart below. HPLC condition was as 
below: Injection volume:10 µL; MWL: 240 nm, 8 REF: 360 nm, 8; elution: H2O: 
acetonitrile = 7:3 (w/o gradient). 
 P-Dex was hydrolyzed in 0.1 N HCl over night to release the Dex. (1 mg poly-
mer to 0.5 mL 0.1 N HCl). Neutralize the system with 0.1 N NaOH with the as same 
volume as HCl used. Withdraw 100 µL, added to 900 µL methanol. Use methanol 
to H2O 9:1 solution further diluted the sample make a series of dilution (10, 20, 25 
times dilution for the triplicate measurement using HPLC as described above). 
3.2.6.2 Polymer parameters characterization of P-Dex 
P-Dex polymer parameters (including weight average molecular weight (Mw), num-
ber of molecular weight (Mn) polydispersity (PDI) and Rayleigh Ratio (RΘ, dn/dc)) 
were analyzed using a combination of AKTÄ pure FPLC system, Wyatt multiangle 
light scattering system and Optilab T-rEX refractive index concentration detector. 
The detailed method was adapted from Wyatt technology protocol.  
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3.2.7 Experimental animals and drug treatment 
 Mice (C57BL/6, 9 weeks old, female), purchased from Jackson Laboratories, 
were randomly assigned to 4 groups with 15 mice per group (P-Dex, Dex, saline 
and healthy control).  All mice were maintained under standard housing conditions.  
All animal experiments were performed in accordance with protocols evaluated 
and approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Nebraska Medical Center.  Following the induction of anesthesia with 
5% inhaled isoflurane, the heads of the mice were shaved and positioned in a Kopf 
stereotaxic head frame (David Kopf Instruments, Tujunga, CA).  Anesthesia was 
maintained with 2% inhaled isoflurane, which was delivered through a nose cone.  
A midline incision was completed, and a 4 mm craniotomy was performed lateral 
to the midline and midway between bregma and lambda to expose the underlying 
somatosensory cortex, taking care not to disturb the dura.  The head frame was 
then positioned beneath a Precision Systems and Instrumentation TBI-0310 (Fair-
fax Station, VA) that administered a 2.5 mm cortical compression (3 mm impactor 
diameter, 5.25 m/sec velocity, 100 msec dwell time). [189]  Following injury, 
Surgicel (Johnson & Johnson, Dallas, TX) was placed over the injury site.  Next, 
the skull cap was put back in place and sealed using dental acrylic.  The skin inci-
sion was closed with 5-0 silk suture, and the incision was infused with 0.5% bupi-
vacaine with 1:200000 epinephrine as topical analgesia.  Following closure, the 
animals were placed in their home cage and healthy animals were left intact.  One 
hour after brain injury, the mice were treated with saline, P-Dex and free dexame-
thasone respectively by tail vein injection.  The dose of free dexamethasone is 28 
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mg/kg and P-Dex is 250 mg/kg (equivalent to 28 mg/kg of dexamethasone).  Mice 
from each group were sacrificed at 6 weeks post-TBI. [184]  Tibias and lumbar 
vertebrae (L4-6) were harvested for evaluation of bone quality.   
3.2.8 Optical imaging based biodistribution study 
 TBI model was established as stated above.  18 mice were randomly assigned 
into 2 groups which are TBI with P-Dex-IRDye administration and healthy with P-
Dex-IRDye administration.  3 mice from each group were sacrificed at 1 day, 7 
days and 14 days after injury.  All mice were perfused with saline followed by 4% 
paraformaldehyde through cardiac puncture.  Major organs and brain were 
collected for optical imaging using Pearl Impulse small animal imaging system (Li-
Cor, NE, USA). Brain was sliced using brain matrix (Kent Scientific, CT, USA) and 
the slices were imaged.  Imaging acquisition condition is dual channel (800 nm 
and white light) with 85 μm resolution.  Images for each mouse were normalized 
using the same intensity scale with a common minimum and maximum value. 
3.2.9 Immunohistochemistry 
 Brain tissues were dehydrated in sucrose overnight and flash frozen in 2-
methylbutane (Fisher Scientific) on dry ice. Brains were cryostat sectioned at 20 
µm thickness, and every section was collected.  3 sections from each mouse and 
5 mice from each group were stained with different antibodies.  In total, 15 sections 
were used from each group to calculate the semi-quantitative fluorescent intensity.  
The slides were blocked with 10% normal donkey/goat serum in TBST (Tris-Buff-
ered Saline with 0.05% Tween 20, pH 7.6) depending on the host of secondary 
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antibodies with 0.25% Triton-X 100 added, incubated with polyclonal anti-Aqua-
porin 4 antibody (1:100) (ab46182, Abcam, Cambridge, MA), polyclonal anti-GFAP 
antibody (1:1000) (ab53554, Abcam, Cambridge, MA), anti-iba1 antibody (1:1000) 
(019-19741, Wako, Japan) and Fluro Jade C for 16 hours at 4˚C.  Then sections 
were incubated with Alexa Fluor® 488 Donkey Anti-Rabbit IgG antibody (1:1000), 
Alexa Fluor® 546 Donkey Anti-Goat IgG antibody (1:1000) (Life Technologies, 
Grand Island, NY) and Alexa Fluor® 647 Goat Anti-Rabbit IgG antibody (1:1000) 
(Life Technologies, Grand Island, NY) if needed in the dark at room temperature 
for one hour.  Slides were mounted with Prolong® Gold Antifade Reagent with 
DAPI (Life Technologies, Grand Island, NY) and dried overnight at room tempera-
ture. 
3.2.10 Micro-CT analysis 
 Hind limbs and lumbar vertebrae were isolated after euthanasia and fixed with 
buffered formalin for no less than 48 hr.  The proximal tibia bone quality 5th lumbar 
vertebra was analyzed using a Skyscan 1172 micro-CT system.  Micro-CT scan-
ning parameters were set as follows: voltage, 55 kV; current, 181 μA; exposure 
time, 845 ms; resolution, 8.89 μm; with aluminum filter (0.5 mm); rotation step = 
0.4°; frame averaging = 4; random movement = 10; using 180° rotation scanning.  
Raw data were reconstructed using NRecon software from Bruker, Belgium.  Tibia 
and 5th lumbar vertebra were oriented using DataViewer software, and all samples 
were 3D-registered.  For show images were rendered using CTvox software.  To 
quantitatively compare the four treatments, the region of interest (ROI) of the tibia 
was selected from the beginning of secondary spongiosa for 40 slides.  The exact 
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slides number was adjusted by the length of the whole tibia.  Only trabecular bone 
was used for micro-CT analyses.  The ROI of the 5th lumbar vertebra was selected 
beginning from secondary spongiosa above the bottom endplate for 40 slides.  The 
exact slides number was adjusted by the length of the whole 5th lumbar vertebral 
body, and only trabecular bone was used for calculation.  The morphometric pa-
rameters, such as bone volume fraction (BV/TV, %), bone surface density (BS/TV, 
1/mm), trabecular pattern factor (Tb.Pf), trabecular number (Tb.N, 1/mm), bone 
mineral density (BMD, mg/cm3), and connectivity were calculated using CTAn soft-
ware. 
3.2.11 Static weight bearing 
The static weight distribution between the left and right hindlimbs was meas-
ured using the incapacitance meter. This apparatus consists of two force transduc-
ers capable of measuring the body weight that the animal places on each hind limb. 
Mice were placed on the incapacitance tester with their hind paws centered on the 
two force transducers and forelimbs laid on the sloped wall.  The body weight dis-
tribution was recorded for each mouse. The weight bearing score is expressed as 
a ratio of the weight placed through the right limb versus the sum of the weights 
placed through both the left and right limbs, with a ratio of 50% resulting from equal 
weight distribution across both hindlimbs. Weight distribution was measured every 
week after TBI for 6 weeks. 
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3.2.12 Neurological Severity Score 
 Mouse behavior after TBI was evaluated using the neurological severity score 
system adapted from [190].  There are 10 tasks, and the mouse will be awarded 1 
point if failed. The 10 tasks are listed below in table 3.1. Specifically, for beam walk, 
if the mouse failed the beam walk on 3 cm width beam, 3 points will be awarded 
and skip 2 cm and 1 cm width beam.  Similarly, if the mouse failed the beam walk 
on 2 cm width beam, 2 points will be awarded and skip 1 cm width beam.  The 
maximal score is 10. The higher the score, the severer the injury to the brain.  
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Table 3.1 Neurological Severity score for mice 
Task Description 
Points 
(success/failure) 
Exit circle 
Ability and initiative to exit a circle of 30 
cm diameter within 3 min 
0/1 
Monopare-
sis/hemiparesis 
Paresis of upper and/or lower limb of 
the contralateral side 
0/1 
Straight walk 
Alertness, initiative, and motor ability to 
walk straight 
0/1 
Startle reflex 
Innate reflex; the mouse will bounce in 
response to a loud hand clap 
0/1 
Seeking behavior 
Physiological behavior as a sign of ‘in-
terest’ in the environment 
0/1 
Beam balancing 
Ability to balance on a beam of 7 mm 
width for at least 10 s 
0/1 
Round stick bal-
ancing 
Ability to balance on a round stick of 5 
mm diameter for at least 10 s 
0/1 
Beam walk: 3 cm 
Ability to cross a 30-cm long beam of 3 
cm width 
0/1 
Beam walk: 2 cm 
Same task, increased difficulty on a 2-
cm wide beam 
0/1 
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Beam walk: 1 cm 
Same task, increased difficulty on a 1-
cm wide beam 
0/1 
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3.2.13 Statistics 
Graphpad Prism version 7.00 was used for statistical analysis.  Log-rank (Man-
tel-Cox) test was used to calculate the statistics for survival curve.  Unpaired t-test 
was used to evaluate the difference between each treatment comparing to 50% 
ideal weight distribution in static weight bearing study. (# P < 0.05, ## P < 0.01, 
### P < 0.001, #### P < 0.0001) One-way ANOVA with Tukey’s test was used to 
evaluate all other outcomes. (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001) 
3.3 Results  
3.3.1 The characterization of P-Dex 
 Dexamethasone standard curve determined by HPLC is shown below in Fig-
ure 3.2.  Dex content in P-Dex determined by HPLC is 112.5±0.2 mg/g.  P-Dex 
has a weight average molecular weight (Mw) of 41.8 kDa, a number average mo-
lecular weight (Mn) of 37.6 kDa and a polydispersity index (PDI) of 1.11, repre-
senting a narrow polydispersity, determined by AKTA pure and MALS system.    
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Figure 3.2  Dexamethasone standard curve determined by HPLC 
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 Figure 3.3  P-Dex curve from AKTA pure and MALS 
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3.3.2 Survival rate of TBI mice with different treatment 
After TBI and drug administration, mice health status was monitored daily.  
Mice death was recorded and summarized in the survival curve in Figure 3.4.  P-
Dex treated mice showed no significant difference in survival rate comparing to the 
healthy group.  Saline (P<0.01) and Dex (P<0.05) treated group showed 
significantly lower survival rate comparing to the healthy group.  No significant dif-
ference (P=0.0947) was observed between saline and P-Dex treated group.  From 
the survival data, there seems to be a trend of increased survival rate after TBI for 
the P-Dex treated group when compared to free Dex treated group.   
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Figure 3.4 Kaplan-Meier survival curves of different treatment after TBI. P-Dex 
treatment showed higher survival rate which is not significantly different comparing 
to the healthy group.  Saline and Dex (P<0.05) treated group showed significantly 
lower survival rate comparing to the healthy group.  No significant difference 
(P=0.0947) was observed between saline and P-Dex treated group.  Log-rank 
(Mantel-Cox) test was used for comparison.  
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3.3.3 P-Dex retained at the injured brain over 14 days. 
IRDye® 800CW labeled P-Dex was administrated 1 hour after injury to TBI 
mice and healthy mice.  From optical imaging, we observed high signal intensity 
at 14 days in the injured area of the brain which was not observed in healthy mice 
at any time points post-injury as seen in Figure 3.5.  P-Dex retained at the injured 
site where the pH of local tissue is acidic because of inflammation and acidosis.  
The linker between the HPMA backbone and Dex was designed as an acid sensi-
tive linker. Dex would be released from P-Dex at these inflammation sites.  Dex in 
vitro release information referred to the previous study. [188]  P-Dex localized at 
the injured site providing sustained dexamethasone releasing.  
From the major organ distribution of P-Dex-IRDye® 800CW shown in Figure 
3.6, P-Dex-IRDye® 800CW shows higher accumulation in TBI mice 1 day after 
injury comparing to healthy mice. 
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Figure 3.5 P-Dex-IRDye® 800CW retention at injured brain over 14 days after in-
jury while no accumulation in the healthy brain 
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Figure 3.6  P-Dex-IRDye® 800CW distribution in liver, kidney, and spleen after TBI 
at 1 day, 7 days and 14days. 
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3.3.4 Immunohistochemistry 
 Immunohistochemistry results in Figure 3.7 showed the Iba1 expression at 
injured area 6 weeks post-TBI in each group.  Saline treated TBI showed signifi-
cantly higher expression of Iba1 comparing to healthy mice (Figure 3.7 *** P < 
0.001).  Dex treatment did not decrease the Iba1 expression comparing to healthy 
(Figure 3.7 ** P < 0.01) and saline treated group (P ≥ 0.05).  P-Dex treated group 
showed significant lower Iba1 expression comparing to saline (Figure 3.7 ** P < 
0.01) and Dex treated group (Figure 3.7 * P < 0.05).  Figure 3.8 showed the rep-
resentative images and semi-quantitative results of Fluoro-Jade C staining results 
which stained degenerated neurons 6 weeks after TBI.  Saline treated group 
showed significantly higher neuronal degeneration comparing to the healthy group 
and P-Dex treated group (Figure 3.8 * P < 0.05).  Dex treatment did not protect 
neurons from death compared to healthy and saline treated group (Figure 3.7 ** P 
< 0.01).  P-Dex showed neuroprotection effect when comparing with Saline treated 
group (Figure 3.8 * P < 0.05).  
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Figure 3.7  Iba1 expression at injured area 6 weeks post TBI.  Saline treated group 
showed significantly higher expression of Iba1 comparing to the healthy group.  
Dex treatment did not decrease the Iba1 expression comparing to healthy and 
saline treated group. P-Dex treated group showed significant lower Iba1 expres-
sion comparing to saline and Dex treated group. One-way ANOVA with Tukey’s 
test was used for comparison. (* P < 0.05, ** P < 0.01, *** P < 0.001) 
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Figure 3.8  Fluoro-Jade C stained degenerated neurons 6 weeks after TBI.  Saline 
treated group showed significantly higher neuronal degeneration comparing to the 
healthy group and P-Dex treated group.  Dex treatment did not protect neurons 
from death compared to healthy and saline treated group.  One-way ANOVA with 
Tukey’s test was used for comparison. (* P < 0.05, ** P < 0.01) 
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3.3.5 Micro-CT analysis 
P-Dex treated TBI mice showed significantly higher bone mineral density (), 
bone volume fraction and trabecular number in both left and right tibias comparing 
to saline and Dex treated TBI mice shown in Figure 3.9.  P-Dex treated TBI mice 
showed significantly lower trabecular pattern factor comparing to saline and Dex 
treated group which indicating the tibia bone microarchitecture is protected by P-
Dex after brain injury. [191]  The connectivity of trabecular bone in tibia was also 
evaluated.  P-Dex treated group showed a trend of higher connectivity in the left 
tibia (p=0.0678) comparing with Dex treated group but is significant higher com-
paring to saline treated group in both left and right tibias and Dex treated mice in 
right tibias.  P-Dex treated TBI mice didn’t show any significant different in all these 
parameters compared with the healthy group.  Dex treatment didn’t show any pro-
tecting effects against bone loss after TBI.  Representative images of proximal 
tibial trabecular bone are shown in Figure 3.11. 
After trabecular bone analysis in proximal tibia by micro-CT, 5th lumbar vertebra 
was also analyzed by micro-CT (Figure 3.10) to evaluate whether the bone loss is 
systemic or only affecting hind limbs.   P-Dex treated and the healthy group showed 
significantly higher bone surface density, bone volume fraction and bone mineral 
density comparing to saline and Dex treated mice.  Dexamethasone treatment did 
not show comparable protection effects as P-Dex treatment after TBI.  The bone 
loss after TBI was found not only in tibias but also lumbar vertebra. 
Higher bone mineral density and bone volume fraction in both tibias and lumbar 
vertebrae with P-Dex treatment indicate the trabecular bone loss was ameliorated 
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comparing to saline and Dex treated group.  Increased trabecular number and 
connectivity of proximal tibia in P-Dex treated group validated the bone loss was 
prevented by P-Dex.  Trabecular architecture was protected by P-Dex treatment 
as decreased trabecular pattern factor was detected in P-Dex treated group.  In-
creased bone surface density in 5th lumbar vertebrae validated the bone loss was 
prevented by P-Dex treatment.   
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Figure 3.9  Micro-CT analysis results of left and right tibias.  P-Dex treated TBI 
mice showed significantly higher bone mineral density, bone volume fraction and 
trabecular number in both left and right tibias comparing to saline and Dex treated 
TBI mice.  P-Dex treated TBI mice showed significantly lower trabecular pattern 
factor comparing to saline and Dex treated.  P-Dex treated group didn’t show sig-
nificant higher connectivity in left tibia (p=0.0678) comparing with Dex treated 
group but is significant higher comparing to saline treated group in both left and 
right tibias and Dex treated mice in right tibias.  P-Dex treated TBI mice didn’t show 
any significant different in all these parameters compared with the healthy group.  
One-way ANOVA with Tukey’s test was used for comparison. (* P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001) 
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Figure 3.10 Micro-CT analysis results of the 5th lumbar vertebra.  P-Dex treated 
and the healthy group showed significantly higher bone surface density, bone vol-
ume fraction and bone mineral density comparing to saline and Dex treated mice.  
P-Dex treated mice was not significantly different compared to healthy mice in 
these parameters. One-way ANOVA with Tukey’s test was used for comparison. 
(* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001) 
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Figure 3.11  Representative images of trabecular bone from secondary spongiosa 
of the proximal tibia.   
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3.3.6 Static weight bearing 
The static weight bearing was evaluated every week after TBI.  The dotted line 
in Figure 3.12 represents the ideal equal weight distribution between left and right 
limbs.  The data from each group was compared to the ideal equal weight distribu-
tion line.  Saline group showed significant more left limb weight distribution com-
paring to the ideal equal weight distribution line from 2 weeks to 6 weeks based on 
unpaired t-test.  Dex treated mice showed significantly higher weight distribution 
to the right hind limb at 1 week after TBI compared to ideal equal weight distribution, 
however, more weight distributed to the left hind limb from week 2 to week 5 sig-
nificantly. (# P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001) Healthy group 
and P-Dex treated mice showed equal weight distribution between left and right 
hind limbs.  From week 2 to week 5, saline and Dex treated group showed 
significantly more weight distributed to left hind limb comparing to healthy and P-
Dex treated mice. (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001) 
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Figure 3.12  Static weight distribution of hind limbs after TBI.  The dotted line rep-
resents the ideal equal weight distribution between left and right limbs.  Saline 
group showed significant more left limb weight distribution comparing to the ideal 
equal weight distribution line from 2 weeks to 6 weeks based on unpaired t-test.  
(# P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001)  Dex treated mice 
showed significantly higher weight distribution to the right hind limb at 1 week after 
TBI compared to ideal equal weight distribution, however, more weight distributed 
to the left hind limb from week 2 to week 5 significantly. (# P < 0.05, ## P < 0.01, 
### P < 0.001) Healthy group and P-Dex treated mice showed equal weight distri-
bution between left and right hind limbs.  From week 2 to week 5, saline and Dex 
treated group showed significantly more weight distributed to left hind limb com-
paring to healthy and P-Dex treated mice. (One-way ANOVA with Tukey’s test, * 
P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001)  
74 
 
3.3.7 Neurological Severity Score 
After evaluation of mouse behavior every week after TBI, the neurological se-
verity score was summarized in Figure 3.13 below.  There was no significant dif-
ference detected between each group.  Healthy mice have scored 3 points every 
week which was the lowest average score across the 4 groups.   
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Figure 3.13  Neurological Severity Score.  No significant difference was detected 
between each group.  
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3.4 Discussion  
 Mice suffered severe TBI would develop trabecular bone loss systemically in 6 
weeks as evaluated by micro-CT.  Bone Mineral Density in the saline group was 
reduced to ~70% in proximal tibia and ~85% in L5 lumbar vertebrae of the healthy 
mice.  P-Dex treated group showed no significant difference comparing to the 
healthy group but was significantly higher than the saline group.  P-Dex treatment 
ameliorated the bone loss after TBI which was not observed in free Dex treatment.  
Bone Mineral Density in the Dex group was reduced to ~70% in proximal tibia and 
~80% in L5 lumbar vertebrae of the healthy mice.  Dex treatment showed lower 
trabecular bone mineral density comparing to saline treatment although no signif-
icance was observed.  The bone loss is result from decreased bone formation or 
increased bone resorption or both.   After brain injury, certain inflammatory cyto-
kine expression was upregulated.  These upregulated proinflammatory cytokine 
may subsequently impact the calcium and phosphate homeostasis in the body.  
Interrupted homeostasis of calcium and phosphate will impact the bone mass in 
the body.  More studies are needed to validate the hypothesis. 
Static weight distribution revealed more weight distributed to the left limb after 
TBI from 2 weeks to 6 weeks.  This may occur due to the injury location of TBI 
which was on the left hemisphere of the mouse brain.  The impact is on the left 
hemisphere which in responsible for coordinating the movement and motor skills 
of right side of the body.  With Dex treatment, the weight distributed to the left with 
a similar pattern as saline treated group.  P-Dex treatment showed a dramatical 
improvement comparing to saline and Dex treated group.  More weight was 
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distributed to left hind limb after TBI which may cause loading and unloading and 
impaired the balance of the mouse.  The bone loss after TBI was observed sys-
temically not localized to right hindlimb.   
The mice were injected with calcein and tetracycline 7 days and 2 days before 
sacrifice.  After micro-CT scanning, the bone was sectioned for bone histomor-
phometry study.  There was no significant difference found between each group 
which means the bone formation rate at 6 weeks after TBI was the same as a 
healthy group.  The bone loss at 6 weeks after TBI was not caused by impaired 
bone formation rate.  It could be resulted from decreased bone formation at early 
weeks after TBI which need to be further investigated.  P-Dex treatment may be 
able to prevent the bone formation rate decrease by ameliorating neuroinflamma-
tion and correct the cytokine abnormal.  
Immunohistochemistry study showed the protection effects of P-Dex after TBI.  
Fluro Jade C staining which stains degenerated neurons shows ~2 folds increased 
signal intensity in saline and Dex treated group comparing to healthy, and P-Dex 
treated group.  It indicates that P-Dex reduced the neuron death after TBI.  Acti-
vated microglia (Iba1 positive) was reduced in P-Dex treated group in which the 
signal intensity is not significantly different compared to the healthy group.  Dex 
and saline group showed 1.5-2 folds increase in the signal intensity of activated 
microglia comparing to healthy and P-Dex treated group.  Activated microglia are 
associated with increased inflammation in the brain and may lead to neuron de-
generation and death. [192]   
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Optical imaging results suggested that P-Dex had targeted to the injured cortex 
with sustained presence for more than 14 days.  Due to the acidic pH at the injured 
site, dexamethasone would be released slowly from P-Dex by hydrazone bond 
hydrolysis.  From the optical imaging study shown in Figure 3.7, we also found that 
P-Dex accumulated more in the kidney of TBI mice comparing to healthy mice.  In 
the previous study, we proved HPMA copolymer conjugates could detect the early 
phase inflammation in calvarial osteolysis model by presenting high signal intensity 
from optical imaging. [117]  The macromolecular prodrug would accumulate at the 
inflammation site even in the early stage.  More accumulation of the prodrug in the 
TBI kidney indicated that the kidney had inflammation after TBI which correlates 
to the findings from clinics. [193, 194]  It has been reported that mineral and bone 
disorder was common in chronic kidney diseases. [195]  The bone loss might be 
due to the inflammation in the kidney after TBI which needs further investigation.  
The bone formation rate at 1 week to 5 weeks after TBI also needs to be investi-
gated to explore the reason for bone loss after TBI and underlying mechanisms 
that P-Dex could prevent the bone loss. 
3.5 Conclusion 
In this study, we have successfully shown the bone loss after TBI and P-Dex 
could prevent bone loss at 6 weeks.  One single systemic P-Dex treatment ame-
liorated the inflammation in the brain while preserving the neurons from death.  
Further studies on the outcome of TBI at different time are needed to investigate 
the underlying mechanisms which bone loss is prevented by P-Dex treatment after 
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brain injury.  This may provide future directions in the treatment of TBI and improve 
both survival and life quality after brain injury. 
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CHAPTER 4. A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effec-
tively Ameliorates Dextran Sulfate Sodium-induced Ulcerative Colitis in Mice 
4.1 Introduction 
 As discussed in previous chapters, HPMA based macromolecular copolymers 
provide the drug delivery platform in the treatment of trauma-induced inflammation.  
P-Dex successfully ameliorated neuroinflammation.  When inflammation affects GI 
tract, it causes inflammatory bowel disease. Inflammatory bowel disease is a gen-
eral name of two diseases which is Crohn’s Disease and Ulcerative Colitis.  Ulcer-
ative Colitis is a chronic inflammation.  To further explore the application of the 
drug delivery platform, we want to test whether the HPMA copolymer could target 
to the inflamed colon.  In this chapter, we will focus on the treatment of dextran 
sulfate sodium-induced ulcerative colitis in mice using macromolecular prodrug 
delivering Janus Kinase inhibitor. This work has been published in pharmaceutical 
research. [196] 
 Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) resulting 
in a chronic and relapsing inflammatory response in the colon, affecting approxi-
mately 1 million Americans, resulting in substantial disability. [23-26]  Approxi-
mately 38,000 new cases of UC per year are reported in the United States, [26]  
with the related annual direct or indirect costs estimated to be $8.1-14.9 billion. [27]  
The current treatment of IBD includes anti-inflammatory agents (e.g., glucocorti-
coids and 5-aminosalicylates) and immunosuppressants (e.g., tumor necrosis fac-
tor (TNF) inhibitors and anti-integrin antibodies). [28, 29]  Clinical use of these 
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medications for moderate to severe UC, however, only result in sustained remis-
sion in less than 30% of the time.  Around 20 to 30% of patients with UC eventually 
would need colectomy, which is a complex procedure with complications. [30]  Cur-
rently, there is no cure for UC, and there is an urgent need for a new therapy to 
augment the natural progression of the disease.  
 Tofacitinib (Tofa) is a Janus Kinase inhibitor that has first been approved by the 
US FDA for treatment of rheumatoid arthritis (moderate to severe) in patients who 
had an inadequate response or intolerance to methotrexate.  Recently, it has been 
approved as a new treatment for moderate to severely active UC.  As an immuno-
suppressant, however, its dose-dependent toxicities, which may be partially 
attributed to its ubiquitous systemic distribution, has raised concerns. [197]  To 
limit its systemic exposure, Tofa was conjugated to an N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer via a carbamate bond to form a macromolec-
ular prodrug. [198]  We hypothesized that after systemic administration, the pro-
drug would passively target and subsequently be internalized by inflammatory cells 
at the intestinal inflammatory lesions, after which the prodrug may be activated 
subcellularly to provide a sustained local presence of Tofa, leading to effective 
resolution of the inflammatory processes with limited systemic immune suppres-
sion. 
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4.2 Materials and Methods  
4.2.1 Instruments 
1H and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Var-
ian, Palo Alto, CA, USA).  ÄKTA Pure system (GE HealthCare, Chicago, IL, USA) 
equipped with UV detector and Superdex 200 increase column 10/300 GL, multi-
angle light scattering (MALS) detector (Wyatt, Santa Barbara, CA, USA) and 
differential refractive index (dRI) detector (Wyatt, Santa Barbara, CA, USA) were 
used to determine the copolymers’ weight average molecular weight (Mw) and 
number average molecular weight (Mn).  Drug content was analyzed on an Agilent 
1100 HPLC system (Santa Clara, CA, USA) with a Hypersil™ ODS C18 Column 
(Thermo Scientific, Waltham, MA, USA).  Paraffin-embedded tissue sectioning was 
done using a Leica RM2255 rotary microtome (Buffalo Grove, IL, USA).  Histology 
slides were scanned by a VENTANA iScanner HT (Tucson, AZ, USA).  Immuno-
fluorescence labeled slides were analyzed using a ZEISS LSM 800 confocal mi-
croscope (Peabody, MA, USA).  Live animals were imaged using the LI-COR® 
Pearl imaging system (Lincoln, NE, USA).  The endoscope used for the colitis 
scoring was purchased from Gradient Lens Corporation® (Rochester, NY, USA).  
Isoflurane vaporizer (Midmark Corp, Dayton, OH) was used to anesthetize animals 
during arthritis induction.   
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4.2.2 Materials 
N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic 
acid)-trithiocarbonate were prepared as described previously. [188]  Tofacitinib cit-
rate and Tofacitinib base were provided by Jinlan Pharm-Drugs Technology Co., 
Ltd (Hangzhou, China).  IRDye® 800CW carboxylate was provided by LI-COR, Inc. 
(Lincoln, NE, USA).  Alexa Fluor® 647 NHS ester was provided by Life Technolo-
gies, Inc. (Eugene, OR, USA).  P-Tofa and the fluorescence-labeled P-Tofa were 
prepared according to procedures described previously. [198]  It has a weight-
average molecular weight (Mw) of 30.4 kDa and a polydispersity index (PDI) of 
1.32.  The Tofa content in P-Tofa was found to be ∼13 wt %.  Dextran sulfate 
sodium (DSS, Mw Ca 40,000) was provided by Alfa Aesar (Haverhill, MA, USA).  
All compounds were reagent grade and used without further purification. 
 Swiss Webster mice (8-week old) were purchased from Charles River Labora-
tories, fed a standard diet ad libitum and maintained under standard housing con-
ditions in a University of Nebraska Medical Center (UNMC) animal facility.  All 
animal experiments were performed in accordance with a protocol approved by 
the Institutional Animal Care and Use Committee (IACUC) of UNMC.   
4.2.3 Synthesis of HPMA copolymer-Tofa conjugate (P-Tofa) via RAFT copolymer-
ization 
 HPMA (500 mg, 3.03 mmol) and HEMA-Tofa [198] (101.2 mg, 0.22 mmol) were 
dissolved in anhydrous dimethyl sulfoxide (DMSO, 2.83 mL) with 2,2′-azobisisobu-
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tyronitrile (AIBN, 5.1 mg, 0.02 mmol) as initiator and S,S′-bis(α, α′-dimethyl-α″-ace-
tic acid)-trithiocarbonate (CTA, 4.5mg, 0.02 mmol) as the RAFT agent.  The solu-
tion was purged with argon and polymerized at 60 °C for 48 hr.  The resulting 
polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 200 
mL) twice to remove the unreacted low molecular weight compounds, and then 
dialyzed against ddH2O.  The molecular weight cutoff size of the dialysis tubing 
was 25 kDa of globular protein.  The resulting solution was then lyophilized to af-
ford the final P-Tofa (550 mg).   
 To quantify Tofa loading, P-Tofa (1 mg/mL) was hydrolyzed in 0.01 N NaOH in 
methanol overnight.  The resulting solution was neutralized and analyzed with 
HPLC (mobile phase: acetonitrile/water = 3/1; detection, UV 284 nm; flow rate = 1 
mL/min; injection volume = 10 μL).  The analyses were performed in triplicate.  The 
mean value and standard deviation were obtained with Microsoft Excel. 
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Figure 4.1 The synthesis of a macromolecular prodrug of Tofacitinib P-Tofa 
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4.2.4 Synthesis of P-Tofa-APMA 
 To introduce fluorescent labels to the P-Tofa for biodistribution and immunoflu-
orescence analysis, primary amine was introduced into P-Tofa using the following 
procedure: HPMA (350 mg, 2.45 mmol) and HEMA-Tofa (71 mg, 0.15 mmol) were 
dissolved in anhydrous dimethyl sulfoxide (DMSO, 3 mL), N-(3-aminopropyl) 
methacrylamide hydrochloride (APMA, 4.8 mg, 0.025 mmol), 2,2′-azobisisobu-
tyronitrile (AIBN, 3.6 mg, 0.02 mmol) as initiator and S,S′-bis(α, α′-dimethyl-α″-ace-
tic acid)-trithiocarbonate (CTA, 3.4 mg, 0.01 mmol) as the RAFT agent, placed in 
an ampule, and purged with argon and polymerized at 60 °C for 48 hr.  The result-
ing polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 
200 mL) twice to remove the unreacted low molecular weight compounds, and 
then dialyzed against ddH2O in 25 kDa cutoff dialysis tube.  The amine content of 
the copolymer was determined as 3.56×10-5 mol/g using the ninhydrin assay. 
4.2.5 The synthesis of P-Tofa-IRDye 
 To monitor its distribution after systemic administration, P-Tofa was labeled 
with IRDye® 800CW.  The labeling procedure is briefly described as follows: 
IRDye® 800CW carboxylate (1 mg, 0.9 µmol), N-(3-dimethylaminopropyl)-N’-ethyl-
carbodiimide hydrochloride (EDC, 1.56 mg, 8.1 mmol) and hydroxybenzotriazole 
(HOBt, 0.49 mg, 3.6 mmol) were dissolved in N,N-dimethylformamide (DMF, 1 mL) 
in dark at 21 C and stirred for 30 min.  DIPEA (7 mg, 0.054 mmol) and P-Tofa-
APMA (50 mg, [NH2] = 1.78 µmol) in DMF (1 mL) were added into the reaction 
mixture and then stirred overnight.  The reaction solution was dialyzed to remove 
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DMF and low molecular weight reactants.  P-Tofa-IRDye was then obtained via 
lyophilization with [IRDye® 800CW] = 6.88 ×10-6 mol/g of the conjugate. 
4.2.6 The synthesis of P-Tofa-Alexa 
 To monitor the cellular sequestration of the P-Tofa in the rat after systemic ad-
ministration, P-Tofa was labeled with Alexa Fluor® 647.  The labeling procedure is 
briefly described as follows: Alexa Fluor™ 647 NHS Ester (1 mg, 0.8 µmol), DIPEA 
(3.5 mg, 0.027 mmol) and P-Tofa-APMA (50 mg, [NH2] = 1.78 µmol) were 
dissolved in N,N-dimethylformamide (DMF, 1 mL) in the dark at 21 C and stirred 
overnight.  The reaction solution was dialyzed to remove DMF and low molecular 
weight reactants.  P-Tofa-Alexa was then obtained via lyophilization with [Alexa 
Fluor® 647] = 5.62×10-6 mmol/g of the conjugate. 
4.2.7 Treatment of dextran sulfate sodium (DSS)-induced ulcerative colitis mouse 
model 
Forty 8-week old male Swiss Webster mice were randomly assigned into four 
groups.  Group 1 was designed as a healthy control group, in which the animals 
received sterile water.  Groups 2-4 were designed as saline, Tofa and P-Tofa 
treated group. The experimental groups received 2 cycles of 4% dextran sulfate 
sodium (DSS, Alfa Aesar, MW 40 kDa) as described previously. [199]  Each cycle 
includes seven-day continuous 4% DSS followed by a seven-day continuous ster-
ile water washout.  In Group 2 (Saline), animals received a saline injection on day 
7 post induction.  In Group 3 (Tofa treated), animals received Tofa from day 7 post 
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induction to the end of the study for 21 days.  Tofa was suspended in 0.5% methyl-
cellulose and 0.025% Tween 20 solution and was given once daily by oral gavage 
at a dosing level of 10 mg/kg/day. [200]  In Group 4 (P-Tofa treated), animals re-
ceived a single i.v. injection of P-Tofa on day 7 post induction at a Tofa equivalent 
dose of 210 mg/kg.  The mice’s body weight, stool consistency and presence of 
hematochezia (tested using ColoScreen™ FOB Test Kit, Helena Laboratories™, 
Texas, US) were examined and recorded daily.  The disease activity index (DAI) 
was calculated as the sum of the change of body weight, diarrheal score and the 
bloody stool score (Table 1), according to the method adapted from literature. [201, 
202] 
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Table 4.1 The scoring system for the calculation of the disease activity index 
based on weight loss, stool consistency and the degree of intestinal bleeding 
[201, 202] 
 
 
 
 
Score Weight loss Stool consistency Hemoccult (Blood stool) 
0 none Normal Negative hemoccult 
1 1-5% Mild soft stool Positive hemoccult 
2 6-10% Very soft; wet Blood traces in stool visible 
3 11-20% Watery diarrhea Gross rectal bleeding 
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 Blood was collected using maxillary sampling method weekly starting a week 
before colitis induction until necropsy.  Animals were sacrificed on day 28 after 
24 hours fast.  Blood and major organs (heart, liver, spleen, lung, kidney, small 
intestine, colon, and mesentery lymph nodes) were collected after perfusion.  
The length of colon was measured.  About 1 cm of the distal colon was collected 
for FACs analyses of cell phenotypes from each animal.  The remainder of the 
colon was assigned to histological evaluation. 
4.2.8 Colonoscopy and colitis scoring 
 The endoscope used for colonoscopy with outside diameter 1.85 mm and LED 
light was purchased from Gradient Lens Corporation® (Rochester, NY, USA) 
equipped with a camera from Amscope (Irvine, CA, USA).  The tip was sterilized 
and lubricated with surgical lubricant (Surgilube®, HR Pharmaceuticals, Inc. York, 
PA, USA) prior to imaging of each animal.  Gentle air inflation of the colon was 
achieved by an external air pump (Variable-Speed Peristaltic Tubing Pump, 
Traceable® Products, TX, USA).  Noninvasive images were taken weekly from 
each animal in all groups.  The images were scored by a gastroenterologist (DDE) 
who was blinded to the treatment groups.  The scoring was based on the scoring 
system (Table 2) adapted from the literature. [203]  
  
91 
 
Table 4.2 Endoscopic colitis score based on the observed signs of inflammation. 
[203] 
Score 
Thickening of 
the colon 
Change of vascu-
lar pattern 
Fibrin 
visible 
Granularity of the 
mucosal surface 
0 Transparent Normal None None 
1 Moderate Moderate Little Moderate 
2 Marked Marked Marked Marked 
3 Nontransparent Bleeding Extreme Extreme 
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4.2.9 Histological evaluation 
Collected colon tissue was opened longitudinally and rolled colonic segments 
with mucosa outward into “Swiss rolls” [204], fixed in 4% PFA for 48 hr and then 
paraffin embedded.  The 5 µm cross-sections were used for H&E staining.  The 
section slides stained with H&E staining were scanned using a high-throughput 
bright-field slide scanner. 
The H&E stained slides were histologically graded by a pathologist (SML, who 
was blinded to the group arrangement), using a scoring system (Table 3) adapted 
from literature. [205]  The score for every histopathologic feature was also summed 
for each animal as a total histological score. 
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Table 4.3 Histological grading criteria. [205] 
Parameters Score Histological features 
Inflammation 
0 None 
1 Slight 
2 Moderate 
3 Severe 
Extent 
0 None 
1 Mucosa 
2 Mucosa and submucosa 
3 Transmural 
Regeneration 
0 Complete regeneration or normal tissue 
1 Almost complete regeneration 
2 Regeneration with crypt depletion 
3 Surface epithelium not intact 
4 No tissue repair 
Crypt dam-
age 
0 None 
1 Basal 1/3 damage 
2 Basal 2/3 damage 
94 
 
3 Only surface epithelium lost 
 4 Entire crypt and epithelium lost 
Percent in-
volvement 
1 1–25% 
2 26–50% 
3 51–75% 
4 76–100% 
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4.2.10 P-Tofa biodistribution analyses using optical imaging 
 To understand the biodistribution of P-Tofa, P-Tofa-IRDye® 800CW (0.2 mg 
polymer/mouse, IRDye content 8 × 10− 6 mol/g) was mixed with P-Tofa to a total 
Tofa equivalent dose of 210 mg/kg and intravenously injected into mice exposed 
to DSS (n = 3/time point) on day 7 post-induction.  Healthy mice received the same 
injection that were used as the control (n=3).  Mice were euthanized 1 and 3 days 
post-injection.  Major organs (liver, spleen, kidney, small intestine, colon, and mes-
entery lymph nodes) were collected and imaged using a Pearl® Impulse small an-
imal imaging system (LI-COR, Lincoln, NE).  Image acquiring condition was dual 
channel (800nm and white light) with 85 µm resolution.  The image for each mouse 
was normalized using the same intensity scale with a common minimum and max-
imum value. 
4.2.11 Analysis of P-Tofa internalization and cellular retention with flow cytometry. 
 To analyze cellular biodistribution of P-Tofa, Alexa Flour® 647 labeled P-Tofa 
(P-Tofa-Alexa 647 200 mg polymer/kg mouse) was mixed with P-Tofa to a total 
Tofa equivalent dose of 210 mg/kg and i.v. injected to mice with DSS exposure (n 
= 3/time point) on day 7 post-induction.  Mice were euthanized 1 and 3 days after 
the administration of P-Tofa-Alexa 647.  Blood and major organs (liver, spleen, 
kidney, colon, and mesenchymal lymph nodes) were collected and processed for 
flow cytometry analysis.  Blood cells were marked by the following antibodies: 
BF650-labeled anti-mouse F4/80, BV711-labeled anti-mouse CD11b, BV786-
labeled anti-mouse CD3e, and PE-Cy7-labeled CD19; BV421-labeled anti-mouse 
CD11c, APC-eFluor 780-labeled anti-mouse Ly-6G (BD Biosciences), 
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PE/Dazzle™ 594 anti-mouse CD45 (Biolegend).  The cells were analyzed using 
LSR II Green flow cytometer (BD Biosciences) and FlowJo software (Treestar, Inc., 
San Carlos, CA). 
4.2.12 Immunohistochemistry analysis of P-Tofa cellular uptake at intestinal in-
flammatory site. 
 Mice were fed with 4% DSS received P-Tofa-Alexa 647 (i.v. 200 mg polymer/kg 
mouse, mixed with P-Tofa to a total Tofa equivalent dose of 210 mg/kg) on day 7 
and sacrificed 1 day later.  Colons were collected and prepared for histologic ex-
amination as described above.  Tissue sections (20 µm) were immunohistochem-
ically stained after antigen retrieval using citrate buffer with the following antibodies: 
rabbit anti-IBA1 (Wako, 019-19741, dilution 1:250), rat anti-CD326(EpCAM) (eBi-
oscience, 14-5791-85, dilution 1:250) and rabbit anti-CD146 (Abcam, ab75769, 
dilution 1/250), respectively, overnight at 4 °C after antigen retrieval and 10% nor-
mal goat serum blocking.  Slides incubated with rat anti-CD326 were further incu-
bated with Alexa Fluor 488-labeled goat anti-rat secondary antibody (Thermo 
Fisher scientific, A11006, dilution 1:1000) and slides incubated with rabbit anti-
IBA1 and rabbit anti-CD146 were incubated with Alexa Fluor 488-labeled goat anti-
rabbit secondary antibody (Thermo Fisher scientific, A11008, dilution 1:1000) for 
another 1 hr at 20 °C in the dark.  The stained slides were imaged using a ZEISS 
LSM 800 confocal microscope after mounted in ProLong® Gold antifade mountant 
with DAPI (Thermo Fisher scientific, P36931).  
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4.2.13 Immunocytochemistry 
 Mouse macrophage cell line (J774, ATCC, VA) and human epithelial cell line 
(Caco-2, ATCC, VA) were cultured in 30 mL of culture medium in a T-75 culture 
flask.  Dulbecco's Modified Eagle Medium (L-glutamine, high glucose) supple-
mented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% heat-
inactivated FBS was used.  Cells were incubated in a humidified 5% CO2 incubator 
at 37 ºC.  The cell culture medium was changed every 3 days until the cells reach 
80% confluent.  J774 and Caco-2 cells were detached by trypsin (0.05% trypsin, 
0.53mM EDTA, 6 mL), counted using automated counter Countess II (Invitrogen, 
MA) and seeded at 9104 cells/well onto 12 mm diameter coverslips in 24-well 
plates.  After cells adhere to 12 mm coverslips for 24 hr, the cells were challenged 
with 1 µg/mL lipopolysaccharides (LPSs) for 24 hr.  After activation, cells were 
treated with Alexa Flour®647-labeled P-Tofa (1 mg/mL) in the presence of LPS (1 
µg/mL) for 24 hr.  The cells were incubated with LysoTracker™ Red DND-99 (Life 
Technologies, MA) for 2 hr under complete culture medium.  Cells were then 
washed with PBS, fixed with 4% paraformaldehyde in PBS and mounted with DAPI 
containing mounting media and observed using confocal microscope.  
4.2.14 Tofa and P-Tofa cytotoxicity 
 Cells were allowed to attach for 24 hours after seeding.  Different drugs and 
vehicles were incubated with cells for 24 hours.  Tofa dissolved in DMSO was 
added to the medium at 0.33 µM, 1 µM, and 3.33 µM.  P-Tofa dissolved in saline 
was added to the medium at 5 µM, 15 µM, and 50 µM.  DMSO and saline vehicle 
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were added as control groups.  Cytotoxicity was determined by MTS cell prolifera-
tion colorimetric assay kit (BioVision, California) following manufacture’s proce-
dure. 
4.2.15 DSS-stimulated epithelial cells in the presence or absence of Tofa or P-
Tofa 
 After Caco-2 cells attaching for 24 hours in 96-well plates, the cells were 
challenged with 4% DSS in the complete culture medium as designed below.  After 
treatment, cell proliferation was measured by MTS assay kits according to the 
manufacturer’s procedure on day 2 and day 3.  Results were generated as a 
percentage of healthy control 
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Table 4.4 DSS treated epithelial cells culture schedule 
Day 1 DSS DSS DSS DSS 
Day 2 DSS+Drug Drug DSS+Drug DSS+Drug 
Day 3   Medium DSS 
. 
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4.2.16 Statistical methods 
One-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to 
account for multiple comparisons, was used for data analysis using GraphPad 
Prism Software.  P-values ≤ 0.05 were considered as statistically significant. 
4.3 Results 
4.3.1 Characterization of P-Tofa 
 P-Tofa has a weight average molecular weight (Mw) of 30.4 kDa, a number 
average molecular weight (Mn) of 23 kDa and a polydispersity index (PDI) of 1.32, 
representing a narrow polydispersity, determined by AKTA pure and MALS system.  
The Tofa drug loading in P-Tofa was found to be ~ 13 wt%.   
4.3.2 Disease activity evaluation 
 Rectal bleeding, stool consistency, and body weight changes were monitored 
daily from the beginning of the study.  From day 2 after DSS administration, stool 
hemoccult was observed in each group.  From day 5 after DSS administration, 
rectal bleeding was observed in each group.  There was the resolution of rectal 
bleeding and stool hemoccult testing was negative after the first 7 days water cycle 
in almost all treatment groups. Rectal bleeding resumed with the initiation of the 
second DSS cycle in all animals except the P-Tofa treated group.  In Figure 4.2, 
the data showed disease activity index (DAI) changes including body weight, stool 
consistency, and hemoccult testing.  The P-Tofa group showed lower DAI after 
drug administration at day 7 comparing to free Tofa treated group and saline 
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treated groups.  The DAI of the P-Tofa treated group was significantly lower com-
pared to the saline group (p<0.05) on day 11, 12, 13, 15, 16, 17, 18, 22, 28.  Alt-
hough, the DAI of P-Tofa treated group was not significantly different from the 
healthy group from day 11 to day 17 and day 22 to day 28 except day 23.  The DAI 
of P-Tofa treated group was significantly lower that Tofa treated group on day 13, 
14, 19, 21 and 22.  
 To evaluate colon fibrosis and damage, colon length of the animals was 
measured at necropsy on day 28 (Figure 4.3 A). [206]  P-Tofa treated animals were 
found to have significantly longer colon length than saline and Tofa treated animals 
as seen in the statistical analysis on Figure 4.3 B.  Additionally, there was no sig-
nificant difference found between the Tofa and saline groups about colon length. 
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Figure 4.2  Disease activity index (DAI) of mice.  The DAI from each animal was 
calculated as the sum of the score of stool consistency, body weight change, and 
hemoccult. 
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Figure 4.3 Mice colon length at euthanasia.  A. The representative images of co-
lons from each group.  The colons were straight but not stretched and aligned at 
the ileocecal junction.  The shortened length of the colon tissues from Saline group 
and Tofa treated group indicates the fibrosis resulting from inflammation.  B. Quan-
titative analysis of the colon length (from ileocecal junction to distal end of rectum).  
** P < 0.01, *** P < 0.001, **** P < 0.0001. 
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4.3.3 Colonoscopy evaluation 
 Before DSS administration, mice from each group were imaged using a 
colonoscope, and representative images are shown in Figure 4.4 A D0.  After treat-
ing with 4% DSS for 7 days, all mice showed severe tissue damage as shown in 
Figure 4.4 A D7 except those from the healthy control group.  After treatment for 7 
days, return of normal healthy visualized vasculature pattern was observed only in 
P-Tofa treated group and the healthy control group.  In contrast, the Tofa treated 
group showed thickened colon and granularity on endoscopic grading.  Individuals 
in the P-Tofa treated group showed mild to no damage in the colon which 
correlates to the disease activity index in Figure 4.2.  After the second 4% DSS 
administration cycle, the P-Tofa treated group showed recurrence of inflammatory 
injury on endoscopic examination with noted colonic thickening and disappearance 
of the regular vascular pattern.  The Tofa treated group had continual colonic thick-
ening and granularity through the course of the second DSS cycle through day 14.  
At the end point of the study (D28), most mice in P-Tofa group showed regular 
colonic mucosa or mildly inflamed mucosa on endoscopic imaging.  At day 21 of 
the study, the P-Tofa and Tofa treated group showed significant improvement in 
colonic inflammation visualized on the endoscopic image with the P-Tofa treated 
group having more resolution of inflammatory markers on imaging.  In contrast the 
saline group showed persistent severe colonic inflammation on imaging.  These 
findings correlated well with disease activity index scoring based on the body 
weight change and stool conditions (Figure 4.2) as well as histological evaluation 
shown in Figure 4.5.  As seen in Figure 4.4 B, the semi-quantitative scores from 
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endoscopic observation were significantly varied between the various groups from 
week 2 to week 4 (P < 0.01) with the exception at week 4 when the P-Tofa treated 
group was not significantly different from the healthy control group.  The colonos-
copy results indicated that at the end of the experiment, P-Tofa treated group 
showed no statistically significant difference from the healthy control animals (Fig-
ure 4.4 B). 
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Figure 4.4 Colonoscopy analyses of the animals.  A. Colonoscopy images of the 
mice from different treatment groups at designed time points.  White arrow indi-
cates colon surface irregularities; Green arrow indicates angiogenesis or bleeding.  
B. Semi-quantitative scoring of the colon according to parameters shown in Table 
2.  Significant difference (P<0.01) was shown between each group from week 2 to 
week 4, except P-Tofa treated group, which was not significantly different from the 
healthy control group at week 4 (P>0.05).   
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4.3.4 Histological evaluation 
 The severity of colonic inflammation and the therapeutic effects of the treat-
ments were evaluated by H&E staining of colon sections.  Colon tissues from each 
group were harvested at 28 days post colitis induction at necropsy.  Severe goblet 
cell loss and crypt architecture damage were observed in the saline group as seen 
in Figure 4.5 A.  Mild crypt damages were observed in P-Tofa and Tofa group, 
respectively.  Inflammatory cell infiltration was observed in saline, Tofa and P-Tofa 
treated groups.  There was severe mucosal epithelium damage observed in saline 
group while only mild mucosal epithelium damaged were found in P-Tofa and Tofa 
treated groups.  The H&E stained colon sections were scored by a professional 
pathologist who was blinded to the treatment group (Figure 4.5 B).  The significant 
difference was found in Tofa group and saline group when compared to healthy 
control; however, no significant difference was found between P-Tofa group and 
healthy control. 
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Figure 4.5 Histological analysis of colon tissue. A. Representative images of H&E 
staining were shown.  White arrow indicated mucosal erosion. Black arrow indi-
cated loss of goblet cells and crypt architecture associated with epithelial damage.  
B. Semi-quantitative histological scores according to the grading system shown in 
Table 3.  Significant difference was found between saline, Tofa treated group and 
healthy control group. * P < 0.05, ** P < 0.01 
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4.3.5 Optical imaging-based P-Tofa biodistribution study 
To analyze the P-Tofa biodistribution and prove its inflammatory tissue 
specificity, optical imaging was used.  The results are shown in Figure 4.6.  Mice 
treated with 4% DSS or regular water for 7 days received P-Tofa-IRDye® 800CW 
administration through tail vein injection.  Mice were sacrificed at day 1 and day 3 
day after the drug administration.   As shown in Figure 4.6 A, isolated and perfused 
major organs had P-Tofa-IRDye infrared signal, especially in liver and kidney.  
DSS treated animals’ colon, and mesenchymal lymph nodes (MLNs) had strong 
signals at 1 day after drug administration which was not found in healthy control 
group.  At day 3, the signal decreased in all tissues except liver and kidney.  Figure 
4.6 B showed the semi-quantified signal results.  At day 1 post-injection, no signif-
icant difference in signal intensity was observed in colon between DSS treated and 
healthy control group, but there is a trend (P = 0.1637) that DSS treated group has 
more prodrug accumulation.  At day 3 post-injection, prodrug signal was still 
stronger in DSS treated group which mean P-Tofa could target and be retained at 
the inflammation site.  
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Figure 4.6 Near infrared optical imaging-based analysis of P-Tofa biodistribution.  
A.  Representative ex vivo optical images of major organs, colon and small intes-
tine from ulcerative colitis mice and healthy control mice at day 1 and day 3 post 
P-Tofa-IRDye® 800CW administration.  B.  P-Tofa was detected mainly at liver, 
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kidney, colon and mesenchymal lymph nodes (MLNs) at 1 day post injection.  At 
3 days post injection, drug signal increased at liver and decreased in other organs.  
Higher infrared signal intensity was observed in colon of DSS treated than healthy 
control group but did not reach statistical significance (P = 0.1637). 
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4.3.6 Immunohistochemistry analyses of colon 
The results of immunohistochemistry shown in Figure 4.7 illustrated the P-
Tofa’s biodistribution on cellular level.  The colocalization of Iba1 (a pan-macro-
phage biomarker which can stain macrophage and dendritic cells. [207]) positive 
cells and P-Tofa in lamina propria indicated P-Tofa was internalized by myeloid 
cells such as macrophages.  The colocalization of P-Tofa and CD326+ cells or 
CD146+ cells were not as strong as Iba1+ cells.  The distribution pattern of P-Tofa 
from lamina propria to luminal epithelium supports that the polymeric prodrug orig-
inated from blood stream and migrated to local colon tissue through passive tar-
geting mechanism. 
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Figure 4.7 Representative images of immunohistochemistry from DSS treated 
mice. Green signal showed different antibody staining (anti-Iba1, anti-CD326, and 
anti-CD146).  Red signal showed P-Tofa distribution.  Blue signal showed the nu-
cleus.  Anti-Iba1 stained colon tissue showed strong colocalization of P-Tofa and 
Iba1+ cells (yellow color).  Anti-CD326 stained tissue did not show strong colocali-
zation of CD326+ cells and P-Tofa.  Some colocalization was observed in anti-
CD146 stained slides. 
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4.3.7 P-Tofa internalization and retention assessed by flow cytometry 
At 1 day after systemic administration, ~70% colon cells internalized P-Tofa 
and 3 days after injection the amount decreased to ~40% as shown in Figure 4.8 
A.  This finding from flow cytometry correlated with optical imaging results.  Large 
number of cells in blood, liver and kidney also internalized P-Tofa at 1 day and 3 
days post-injection.  The percentage of cells in spleen internalizing P-Tofa de-
creased from day 1 to day 3.  Figure 4.8 B showed the P-Tofa+ cells percentage in 
different organs which were CD45-.  This result showed the residential cells inter-
nalized P-Tofa in different organs.  The percentage of residential colon cells in-
creased from ~30% at day 1 to ~60% at day 3 which proved P-Tofa retained at 
inflamed colon.  The same trend was observed in spleen.  Figure 4.8 C showed 
cell profile in blood internalizing P-Tofa.  At both day 1 and day 3, ~30-40% CD3+ 
(T cells) and ~30-40% CD11b+ (myeloid cells) cells internalized and retained P-
Tofa.  Specifically, the percentage of CD11b+CD11c+ (dendritic cells) cells inter-
nalizing P-Tofa increased from day 1 to day 3.  Macrophages (CD11b+F4/80+) 
showed less P-Tofa internalization in blood than dendritic cells.  This result corre-
lated with the immunohistochemistry findings of P-Tofa’s colocalization with Iba1+ 
cells.  
 
118 
 
 
Figure 4.8 Flow cytometry analysis of in vivo cellular sequestration of P-Tofa. A. 
The percentage of P-Tofa+ cells in different organ at 1 day (D 1) and 3 days (D 3) 
after injection in mice with 7-day 4% DSS oral gavage.  B The percentage of resi-
dential P-Tofa+ cells (CD45-) in different organs at 1 day (D 1) and 3 days (D 3) 
after injection.  C. The percentage of P-Tofa+ cell phenotypes in the blood.  
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4.3.8 Immunocytochemistry 
To further investigate the internalization and subcellular trafficking of P-Tofa, 
epithelial cells (Caco2) and macrophage (J774) were cultured in vitro.  Alexa 
Flour®647 labeled P-Tofa was incubated with cells and imaged.  P-Tofa-Alexa 647 
signal was less in epithelial cells compared with macrophage.  P-Tofa-Alexa 647 
internalized by J774 was sequestered in lysosomes as shown in Figure 4.9 (colo-
calization of red signal and green signal).  Within the lysosomal compartment, the 
environment is acidic, and tofacitinib could be gradually released from P-Tofa pol-
ymer, which may lead to sustained amelioration of the inflammation.  
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Figure 4.9 P-Tofa-Alexa 647 internalization by macrophage (J774) and epithelial 
cells (Caco2).  Lysosomes stained with LysoTracker (Green), P-Tofa labeled with 
Alexa Flour®647 (Red), Nuclei (Blue).  P-Tofa-Alexa 647 internalized by J774 was 
sequestered in lysosomes (colocalization). Less drug was internalized in epithelial 
cells compared with macrophage. 
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4.3.9 Cytotoxicity 
As described in the previous study, Tofa content in P-Tofa is ~13 wt% (data not 
shown). As Tofa releasing from P-Tofa is slow, we choose 15 µM P-Tofa to corre-
spond 1 µM Tofa dosage. 3 different dosage were selected for Tofa or P-Tofa 
group. Proliferation was expressed as to healthy After incubation for 3 hours, no 
significant different in proliferation was observed compared with vehicle and 
healthy group as shown in Figure 4.9 A-B.  
4.3.10 The effects of Tofa and P-Tofa to epithelial cells (Caco2) with presence of 
DSS 
Epithelial cells were incubated with 4% DSS in cell culture medium for 24 hours 
before Tofa or P-Tofa treatment. At the time of drug introduction, the cells were 
exposed to either 4% DSS or regular cell culture medium. 24 hours after drug ex-
posure, proliferation was measure and normalized to healthy control as shown in 
Figure 4.9 C-D. No significant difference was found between no treatment, vehicle 
and drug treated groups. Another set of study was continued with longer incubation 
as shown in Figure 4.9 E-F. After 24 hours of drug exposure with 4% DSS in pres-
ence, the cells were exposed to either 4% DSS or regular cell culture medium for 
an additional 24 hours. Only 3.33 µM Tofa treatment group was found significantly 
lower compared with no treatment group in cell proliferation. As seen in Figure 4.9, 
the proliferation of 3.33 µM Tofa treated epithelial cells seems to be lower 
compared with vehicle group although not significant. The lower proliferation rate 
may indicate 3.33 µM Tofa might be toxic to epithelial cells.  
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Figure 4.9 Cytotoxicity of Tofa and P-Tofa on endothelial cell (Caco2) and 
macrophage (J774). Cell proliferation of endothelial cell (Caco2) with the presence 
of Tofa and P-Tofa after treated with DSS. A-B. 3 different Tofa and P-Tofa con-
centration were used to investigate the toxicity to macrophage and epithelial cells. 
Therapeutic efficacy of Tofa and P-Tofa to DSS treated epithelial cells. C-D 
showed the proliferation rate of epithelial cells after treated with 4% DSS for 24 
hours and treated with drug with the presence of DSS or with regular medium. E-
F showed the proliferation rate of epithelial cells after treated with 4% DSS for 24 
hours and drug with DSS for 24 hours and with the presence of DSS or with regular 
medium.  * P < 0.05 
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4.4 Discussion  
Tofacitinib, a pan-JAK inhibitor, was approved in 2012 for the treatment of rheu-
matoid arthritis and in 2017 it was approved for the treatment of psoriatic arthritis 
by US FDA.  The approval was expanded in May 2018 for the treatment of moder-
ate to severe ulcerative colitis.  Tofacitinib is a small molecule administered orally 
that target cytokine signaling by preventing phosphorylation of Janus kinases as-
sociated cytokine receptor. Subsequently, phosphorylation of signal transducers 
and activators of transcription (STATs) that relay Janus kinase signaling and tran-
scription of cytokines in the nucleus will be diminished. Key cytokines in the 
pathogenesis of ulcerative colitis such as IL-4, IL-5, IL-13 and IL-23 are targeted 
by Janus kinase inhibitors. [208, 209]  Tofacitinib was found to be effective in phase 
2 and 3 trials in moderate-severe ulcerative colitis at a dosage of 3 mg, 5 mg, 10 
mg and 15 mg twice daily.  Higher dosage showed faster and better remission, 
[210, 211] however, Tofacitinib, as a low molecular weight drug, frequently cause 
dose-dependent toxicities as a result of off-target side effect.  Its immunosuppres-
sive property contributes to the increased risk of infection, particularly herpetic in-
fections.  Understanding the expended application of Tofacitinib in the clinical 
management from rheumatoid arthritis to ulcerative colitis, and its dose-dependent 
toxicities limitations associated with the immune suppression, we proposed to de-
velop a macromolecular prodrug nanomedicine of Tofacitinib in this study to incor-
porate disease associated inflammatory tissue specificity. We aimed to achieve 
disease associated organ/tissue-specific anti-inflammatory effects, which may po-
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tentiate the therapeutic efficacy and mitigate the systemic adverse effects associ-
ated with Tofa dosage, by enhancing its accumulation at active inflammation in 
colonic tissue.  
For inflammatory bowel disease (IBD), loss of integrity of intestinal epithelium 
has been shown to play a key pathogenic role. [212]  Tofa, as a JAK inhibitor, 
prevents epithelial damage by inhibiting Th2-type cytokines (IL-4, IL-5 and IL-13) 
expression.  IL-4 plays an important role in naïve T cells differentiation into Th2 
cells.  IL-5 has been shown to be a key mediator in eosinophil activation and pro-
motion of B cell growth.  Additionally, IL-13 promotes fibrosis and induces apopto-
sis and degradation of tight junctions in epithelial cells. [208, 209]  According to 
our previous study, IL-4 activated bone marrow macrophages were repressed for 
a longer time when pretreated by P-Tofa compared to Tofa. [198]  The macro-
phage activation biomarker (Arg1, Ym1/2 and Fizz1) were significantly lower in P-
Tofa group quantified by qPCR which indicated P-Tofa’s sustained anti-inflamma-
tory activity in relation to tofacitinib.  
Previously, the prodrug dexamethasone HPMA copolymer conjugate (P-Dex) 
and P-Tofa have been found to passively target and be retained at the sites of 
inflammation due to its extravasation through leaky vasculature and inflammatory 
cell-mediated sequestration (ELVIS) mechanism, providing sustained inflamma-
tion amelioration. [146]  This observation has been validated in multiple inflamma-
tory disease animal models, including rheumatoid arthritis, lupus nephritis, aseptic 
implant loosening and ulcerative colitis. [119, 122, 198, 213, 214]  P-Tofa showed 
a robust inflammation targeting effect as shown in optical imaging (Figure 4.6) and 
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was retained at inflamed tissue as shown in Figure 4.8 with increased internaliza-
tion by residential colon cells.  P-Tofa showed strong targeting to inflamed colon 
comparing to healthy control at 1 day post-injection.  The spleen showed high sig-
nal intensity as shown in Figure 4.6 and Figure 4.8 A.  The spleen served as the 
main filter for blood-borne pathogens and antigens in the body. [215]  It also served 
as a site for monocytes storage.  When inflammation presents in the body, the 
spleen could deploy the monocytes rapidly to regulate inflammation. [216]  When 
P-Tofa is injected to DSS treated mice, it was internalized by macrophages through 
endocytosis and retained at inflammation site, in this case, the inflamed colon as 
shown in Figure 4.7 and 4.7.  After P-Tofa passively targeted to the inflamed colon, 
it was sequestered in dendritic cells/macrophages as shown in Figure 4.7 and 4.7 
C.  The high signal of P-Tofa-IRDye ® 800CW was detected in the liver and kidney.  
There were two possible reasons for this high accumulation. One may be attributed 
to liver inflammation as reported in literature that DSS promoted hepatic inflamma-
tion. [217]  Mild liver inflammation was also observed during histological evaluation 
(data not shown). The other possible explanation is that the liver and kidney are 
clearance organs which would process P-Tofa, leading to high P-Tofa presence 
as shown in Figure 4.6 and 4.7.   
Since P-Tofa was injected through tail vein, its distribution should be from blood 
stream to the epithelium which correlated the findings shown in Figure 4.6.  Epi-
thelial or endothelial cells didn’t internalize P-Tofa as much as dendritic cells/mac-
rophage.  These findings further validated the ELVIS (extravasation through leaky 
vasculature and inflammatory cell-mediated sequestration) mechanism. [146]  P-
126 
 
Tofa passively targeted and retained at the inflammation site mediated by dendritic 
cells/macrophages.  As in vitro cell culture shows in Figure 4.9, P-Tofa trafficked 
into lysosomal compartment subcellular.  Due to the acidic pH in lysosomes, Tofa 
was released from polymer by cleaving the carbamate bond.  Compared to Tofa’s 
ubiquitous distribution, P-Tofa could passively target to inflammation sites and re-
lease Tofa locally to achieve sustained inflammation amelioration. 
From Figure 4.2, the DAI results combining body weight change, stool con-
sistency and hemoccult showed significant difference between P-Tofa and saline 
group.  P-Tofa showed superior therapeutic efficacy.  Although Tofa did show 
significant difference compared with saline but did not show significant difference 
compared with healthy control at some days, the overall outcome of daily Tofa 
treatment was not as good as single P-Tofa injection.  At necropsy at day 28, the 
colon length was measured as shown in Figure 4.3.  Shortened colon length in 
saline and Tofa group indicating inflammation and colon damage which was not 
found in P-Tofa group compared with healthy control.  Colonoscopy visualized the 
colonic inflammation in the mucosa throughout the study.  The aforementioned 
results also correlated with histology staining.  
In addition to amplifying the therapeutic efficacy, the macromolecular prodrug 
may also reduce typical side effects associated with parent drug treatment. [119, 
198, 214]  To assess the safety profile of P-Tofa, the hematology and liver function 
profiles of inflammatory rats treated with P-Tofa have been evaluated previously. 
[198]  The lower levels of WBC count and ALP were detected in the P-Tofa group 
when compared to the Tofa treated group at the later stage of the treatment.  These 
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parameters were still within the normal range according to the vendor (Charles 
River Laboratories, Inc. MA).  This reduction of WBC number may be interpreted 
as Tofa’s immunosuppressive effect or the attenuation of the systemic inflamma-
tion.  More comprehensive toxicity studies are necessary to accurately define the 
P-Tofa’s safety profile in relevant experimental disease models. 
In the present study, DSS-induced ulcerative colitis mouse model was chosen 
for providing proof of concept in the investigation of a potential novel therapeutic 
intervention of ulcerative colitis.  DSS-induced ulcerative colitis, as well as other 
chemical-induced colitis models, exhibited several clinical and histological features 
of inflammatory bowel disease. [218-220]  The inflammation was not directly 
induced by DSS.  Rather it damages epithelial cells and expose lamina propria 
and induce subsequent immune cells infiltration. [221]  Besides chemical-induced 
colitis model, a transgenic model such as the TRUC mouse model may better re-
capitulate the complex pathophysiology of human ulcerative colitis.  The TRUC 
model disrupts transcriptional regulatory T-bet in the innate immune system of 
Rag2-/- mice. [222]  To fully evaluate the therapeutic efficacy and safety profile of 
P-Tofa, it should be further evaluated on the TRUC mouse model.  Tofacitinib as 
a pan-JAK inhibitor also showed promising therapeutic effects in Crohn’s Disease 
(CD) from the clinical study.  CD, as an immune disease, affecting multiple loca-
tions in the body which is not only located on the colon.  Therefore, to test the 
therapeutic potential of P-Tofa for CD, it needs to be tested on CD-relevant pre-
clinical models. 
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The water-soluble, biocompatible HPMA copolymer itself is non-degradable in 
the body which may pose a limitation of P-Tofa and raise potential safety concern 
associated with its long-term clinical utility.  Although the molecular weight of P-
Tofa is around 35kDa which could be excreted from the body eventually, a de-
gradable HPMA copolymer may be further developed to address this concern. [223] 
4.5 Conclusion 
In this study, we validated the therapeutic efficacy of a macromolecular prodrug 
of a Janus Kinase (JAK) inhibitor, Tofacitinib (P-Tofa) in the treatment of DSS-
induced chronic ulcerative colitis mouse model.  A single systemic administration 
of P-Tofa provided superior and sustained therapeutic efficacy comparing to dose 
equivalent daily Tofa treatment.  This improvement may be attributed to P-Tofa’s 
passive targeting to inflamed colon tissue and the subsequent sequestration by 
inflammatory cells at the pathology.  Further efficacy and safety evaluation on other 
UC and Crohn’s disease models is necessary to fully establish the potential utility 
of P-Tofa as a new therapy for improved treatment of inflammatory bowel diseases 
(IBD). 
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CHAPTER 5.  Salvianic Acid A Liposomal Formulation Ameliorates Ischemia-
Reperfusion Injury through Local Extracorporeal Vascular Circuit 
 
5.1 Introduction 
 Recent years, more and more pharmacologically potent drug candidates fail at 
a late stage of clinical evaluation due to their undesirable pharmacokinetics (PK) 
and toxicity that arises from the systemic and off-target distribution.  To solve this 
problem, drug molecule structural design has been manipulated to adjust their 
binding affinity to plasma proteins and interaction with cells in the circulation, which 
may modify the PK parameters. Such strategies, however, cannot provide precise 
control of the drug deposition at the site of pathology or the duration of the local 
drug retention. Recent advances in nanotechnologies have led to the development 
of nanomedicine formulations that hold the promise of achieving precise drug dis-
tribution at the desired sites of action. No matter how the nanomedicines were 
modified with targeting moieties, there is still off-target distributions when adminis-
trated systemically. In the past decades, only a small number of them, however, 
have been approved for clinical use and in general, have not met the anticipated 
therapeutic benefit to patients. [224, 225]  Indeed, the precise control of in vivo 
drug concentration is still a major challenge, which is similarly important as the 
drug discovery process.  Therefore, we proposed the creation of Local Extracor-
poreal Vascular Circuits (LEVC) for the precise drug delivery to therapeutically tar-
geted sites of organ/tissue pathology. Specifically, the LEVC uses minimally 
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invasive surgical procedures and the application of advanced endovascular sur-
gery techniques to isolate a particular site of organ or tissue pathology (e.g., brain, 
liver, lung, spleen, kidney, limb, etc.) from the central circulation. In addition to a 
pump that would circulate the blood through the isolated organ/tissues, an oxygen-
ator, a dialysis unit for removal of metabolic wastes, drug introduction ports, and 
blood warming/cooling units can also be introduced into the circuit. [226]  By cre-
ating such a circuit, one could ensure ~100% bioavailability of a therapeutic agent 
for the targeted tissue/organ.  The local circulation can be maintained for extended 
periods to achieve the necessary therapeutic goals.  Other parameters (e.g., drug 
concentration, local temperature, acidity, oxygen level, flow rate, flow rhythm, etc.) 
of the drug delivery process through LEVC can also be directly regulated to 
achieve the optimal therapeutic and safety outcome.  As the proposed LEVC is 
isolated from the main body circulation, no drug will be left in the blodd circulation.  
After suturing the isolated site to the systemic blood flow, no drug will be distributed 
to the systemic circulation from blood vessels.  The only exposure will be the drug 
retained at the isolated site redistribute through lymphatic drainage system.  The 
dose-limiting organ/tissues such as the liver, kidney, heart, etc. will have minimal 
exposure of the drug administered via LEVC. 
 LEVC may benefit or even provide cures to those conditions which are suitable 
for drug treatment but have not been successfully treated due to the limited drug 
accessibility or toxicity.  These conditions include inoperable cancer, cancer me-
tastasis, organ failure and conditioning organs for transplantation.  The introduc-
tion of LEVC into human patients must first be validated in animal models of 
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disease.  Fortunately, a broad spectrum of human disease models has been es-
tablished using rodents, with mouse model being the most abundant.  To create a 
LEVC surgically on a particular limb is straightforward. Therefore, I anticipate uti-
lizing LEVC to treat conditions such as limb ischemia-reperfusion injury, chronic 
infection. The creation of LEVC in mouse models will necessitate skillful microvas-
cular surgery and the accompanying set of instrumentation that would fit the anat-
omy of rodents. 
As discussed in chapter 1, ischemia-reperfusion injury, affecting a large popu-
lation in the US, undergoes inflammatory reactions after the restoration of blood 
flow which is initiated by reactive oxygen species.  Further exploration of a 
therapeutic or preventive candidate for ischemia-reperfusion injury will be 
discussed in this chapter. 
Hemorrhage from extremity injuries is the most common cause of preventable 
death in both civilian and battlefield medicine.  Arterial tourniquet used clinically is 
the most common method to achieve hemostasis in both trauma and bloodless 
surgical fields in surgery.  However, the blood reperfusion after the stopping of 
blood flow can cause the ischemia-reperfusion injury.  The injury includes skeletal 
muscle necrosis, apoptosis, and severe impairment of neuromuscular junction.  
The ischemia-reperfusion injury can impede long-term recovery of skeletal muscle 
contraction, cause permanent neurological deficits and limit the clinical use of a 
tourniquet.  We clearly understand that the longer tourniquet time is needed in 
many emergency cases for effective life-saving especially in the battlefield.  Ex-
cess production of reactive oxygen species (ROS) received much attention as a 
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critical factor in the genesis of reperfusion injury. [227]  Scavenging ROS becomes 
the novel drug targets in the treatment of ischemia-reperfusion injury.  Salvianic 
Acid A (Danshensu or SAA), a water-soluble active compound isolated from the 
salvia miltiorrhizae (Danshen), was found to be a potent radical scavenger and 
antioxidant. [228]  As an antioxidant, stabilization is very important to preserve the 
potency of the radical scavenging.  Decreased efficacy of antioxidation before the 
administration will affect the therapeutic effect.  In this chapter, we developed a 
Vitamin E incorporated liposomal formulation to deliver SAA which will enhance 
the antioxidation efficacy of SAA.  We will utilize the innovative drug delivery 
method, LEVC (Local extracorporeal vascular circuits). With this drug delivery 
method, the drug distribution to the injury area will be promoted, and the systemic 
toxicity to other organs like liver, spleen, and kidney will be lowered.  Especially for 
the ischemia-reperfusion injury model, local vascular perfusion before the restora-
tion of system blood flow could remove all the toxins and metabolic wastes and 
prevent the remote toxicity caused by the ischemia-reperfusion injury to the other 
organs in the body.  
5.2 Materials and Methods  
5.2.1 Materials 
 Cholesterol was purchased from Sigma Aldrich, US.  Lecithin was purchased 
from MP Biomedicals, US.  Vitamin E (α-tocopherol) was purchased from TCI 
AMERICA, US.  Anhydrous methanol, chloroform, and dichloromethane were pur-
chased from ACROS Organics, US.  Salvianic Acid A was purchased from Shilan 
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Technology, Tianjin, China.  Triton-X 100 was purchased from Millipore, US.  Hep-
arin Sodium Injection, USP 1000 units/mL was purchased from APP 
Pharmaceuticals US.  IRDye® 800CW carboxylate was purchased from LI-COR, 
Inc. (Lincoln, NE, USA).  All other reagents and solvents, if not specified, were 
purchased from either Sigma-Aldrich (St. Louis, MO, USA) or Acros Organics 
(Morris Plains, NJ, USA).  All compounds were reagent grade and used without 
further purification. 
5.2.2 Instruments 
Liposomes were prepared with Avanti® Mini-Extruder (Avanti Polar Lipids, Al-
abaster, AL, USA).  The SAA loading was determined by HPLC analysis performed 
on an Agilent 1100 HPLC system (Agilent Technologies, Inc., Santa Clara, CA) 
with a Hypersil™ ODS C18 Columns (Thermo Scientific, Waltham, MA).  LEVC 
was created with PS-200 pressure servo control pump and miniature gas ex-
change oxygenator from Living Systems Instrumentation, US.  Femoral vein cath-
eters for mouse were purchased from SAI infusion, US.  Dissection microscope 
was purchased from World Precision Instruments, US.   
5.2.3 Liposomes preparation 
Liposomes were prepared by the thin film hydration method [229, 230] or re-
verse phase evaporation method. [231, 232]  For thin film hydration method, a lipid 
film (40 mg lecithin, 9.7mg cholesterol, and 0.3mg α-tocopherol) was formed in a 
round-bottom flask via rotary evaporation (Buchi, Switzerland) of chloroform and 
methanol (2:1), and further dried under a nitrogen flow.  The lipid film was then 
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hydrated with 50 mg SAA in 1 mL injectable saline to form liposomes. The size 
and polydispersity of the liposomes were reduced by repeated extrusion of the 
dispersion through 0.2 µm polycarbonate filter (Whatman, USA) mounted in an 
Avanti® Mini-Extruder (Avanti Polar Lipids, Alabaster, AL, USA).  The formulated 
liposome was purified with a PD-10 column using a spin protocol to remove free 
SAA.  For the reverse phase evaporation method, lecithin (40 mg), cholesterol (9.7 
mg) and α-tocopherol (0.3 mg) were dissolved in DCM (3 mL) in a round bottom 
flask.  SAA solution (50 mg in 1 mL injectable saline) was added into the lipid 
solution.  The aqueous phase and DCM were kept at a volume ratio of 1:3.  The 
mixture was stirred at 1500 rpm/min for 10 minutes. DCM in the resulting emulsion 
was removed using a rotary evaporator at 500 mbar for 1 hour and 200 mbar for 1 
hour at ambient temperature. Using an Avanti® Mini-Extruder (Avanti Polar Lipids, 
Alabaster, AL, USA), the resulting product was extruded through a 0.2 μm mem-
brane 11 times to obtain the liposome with desirable size. The formulated liposome 
was purified with a PD-10 column using a spin protocol to remove free SAA. 
5.2.4 Liposomes characterization 
A Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK) was used 
to analyze the effective hydrodynamic diameters and polydispersity index (PDI) of 
liposomes. SAA calibration curve was first established on the Agilent 1100 HPLC 
with a Hypersil™ ODS C18 Columns. To quantify the loading efficiency of SAA in 
the liposomes, liposomes were brokedown by 5% Triton-X 100 with sonication. 
The SAA was quantified according to an SAA calibration by HPLC.  
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5.2.5 Microsurgery and experimental treatment 
All mice were maintained under standard housing conditions.  All animal exper-
iments were performed in accordance with protocols evaluated and approved by 
the Institutional Animal Care and Use Committee (IACUC) of the University of Ne-
braska Medical Center.  CD-1 mice (~30 g body weight from Charles River, US) 
will be utilized in IR (ischemia-reperfusion) injury or sham groups.  2% of inhalant 
isoflurane was used for continuous anesthesia.  Water circulating heat pad was 
utilized to keep body temperature during surgery.  Hair around the left hind limb 
was removed and disinfected with 3 alternating cycles of povidone-iodine and al-
cohol.  Ischemia-reperfusion injury model establishment will be described first.  Us-
ing small surgical scissors, make a curved incision in the skin over the femoral 
artery. Bluntly dissect and secure surrounding tissues using retractors and mag-
netic retractor fixators to locate the femoral artery. Moisten the tissues periodically 
using saline for irrigation.  Apply saline using a sterile cotton-tipped applicator.  
Isolate the femoral artery using forceps.  Gently separate the nerve from the vas-
cular bundle using fine-tipped forceps.  Avoid puncturing the vein, and do not dam-
age the nerve.  Push the nerve away from the bundle to avoid stimulating it.  Pass 
a strand of 7-0 suture underneath the proximal end of the femoral artery or vein.  
Occlude the vessel using double knots. Close the skin with 4-0 nylon suture con-
tinuously for all mice except LEVC perfusion group. Ligation was removed by cut-
ting off using scissors.  To create a local extracorporeal vasculature circuit, gently 
separate the femoral vein from the femoral artery and locate the femoral bifurcation.  
Use the micro-vessel clamp to restrict the blood flow and maximize the exposure 
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of the vessel.  Use the micro-surgical scissor to make an incision large enough to 
pass the catheter, in line with the vessel between the clamps.  Insert the femoral 
artery/vein catheter (MFV-02 from Sai-infusion Technologies) with the help of fine-
tipped forceps lifting the open window of the vessel.  When the catheter was fully 
inserted, secure the catheter with 7-0 suture.  Drug administration Connect the 
catheter of the vein to the inlet of the pump and catheter of the artery to the outlet 
of the pump.  The pump system should be prefilled with heparinized mice blood 
(from the donor mice), and liposome encapsulated SAA (50 mg/kg). Circulate the 
system under the pressure at 50 mmHg for 60 minutes. Then flush the leg with 
heparinized blood only. This procedure is to minimize the redistribution of the drug 
in the femoral tissue. The vessels were closed with 12-0 nylon suture (12-0 Nylon, 
microsurgery instruments, Inc.).  Surgifoam gelatin sponge was used to stop bleed-
ing.  The skin was sutured with 4-0 nylon suture continuously. The basic setup for 
LEVC is illustrated in Figure 5.1 below. 
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Figure 5.1  Scheme of LEVC system created for mice IR injury model.  
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5.2.6 In situ detection of gastrocnemius muscle contractile force 
20 mice were randomly assigned in Sham (no ischemia), control (no treatment), 
I.V. (liposomes administrated through the tail vein, SAA 5 mg/kg) and LEVC group 
(SAA 50 mg/kg).  Under anesthetized condition (urethane and chloralose, i.p.), the 
mouse was placed on a heating plate maintained at 37 ºC in the prone position. 
Left foot was fastened to a plank by using a self-made needle, leading to left ankle 
at 90º of flexion. The middle and distal end of gastrocnemius muscle were isolated 
and then covered by warmed saline-moistened cotton. Distal end of gastrocnemius 
muscle was sutured and connected to a wide range force transducer (AD Instru-
ments) after the knee joint was fastened to a plank by using another self-made 
needle. Left biceps femoris muscle were split along the muscle fibers to expose 
the sciatic nerve. The distal cut end of sciatic nerve was placed on a bipolar plati-
num electrode and covered by mineral oil wetted cotton. Twenty electrically evoked 
isometric contractions of the gastrocnemius muscle will be obtained. Each con-
traction will last for 5 seconds (10 V, 50 Hz, 0.1 ms pulse) with 25 seconds interval 
between contractions. 
5.2.7 Electrophysiological recording of endplate potentials 
Under anesthetized condition (urethane and chloralose, i.p.) and mechanical 
ventilation, the mouse was placed on a heating plate maintained at 37 ºC in prone 
position.  The middle and distal end of left gastrocnemius muscle was isolated and 
then covered by warmed saline-cotton.  The distal cut end of exposed left sciatic 
nerve was placed on a bipolar platinum electrode and covered by mineral oil wet-
ted cotton.  Endplate potentials were recorded using glass microelectrode filled 
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with 3 M KCl (resistance 8-15 MΩ).  The microelectrode was inserted into the mus-
cle fiber using a micro-manipulator.  The proximity of the electrode to an endplate 
was determined by the presence of miniature endplate potentials.  The sciatic 
nerve stimulation (10 V, 50 Hz, 0.1 ms) induced endplate potentials in 5-s contin-
uous stimulation were digitized and stored in the computer for analyzing the am-
plitude of stimulation-induced endplate potentials. 
5.2.8  Optical imaging based biodistribution analyses 
To understand the biodistribution of the liposomes administrated through a tail 
vein or locally by LEVC, IRDye® 800CW carboxylate was encapsulated in the 
liposomes.  Tail vein injection was done at the time of reperfusion.  The mice were 
monitored using a Pearl® Impulse small animal imaging system (LI-COR, Lincoln, 
NE) 1 hour, 1 day, 2 days, 4 days, 8 days and 12 days after liposomes administra-
tion.  Major organs (liver, spleen, kidney, small intestine, colon, and mesentery 
lymph nodes) were collected and imaged at 1 day after liposomes administration 
using optical imager.  Image acquiring condition was dual channel (800nm and 
white light) with 85 µm resolution.  
5.2.9 Statistcs 
Graphpad Prism version 7.00 was used for statistical analysis.  One-way 
ANOVA with Tukey’s test was used to evaluate all other outcomes. (* P < 0.05, ** 
P < 0.01, **** P < 0.0001) 
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5.3 Results  
5.3.1 Characterization of liposomes 
 The hydrodynamic diameters and polydispersity index (PDI) of liposomes were 
characterized by dynamic light scattering. The diameter is 233.9 nm with PDI 0.17.  
The colloidal stability of liposomes prepared by thin film hydration and reverse 
phase evaporation were tested up to 23 days in 4 °C and 37 °C.  The results from 
dynamic light scattering showed that the liposomes prepared by the thin film hy-
dration method were more stable compared to the liposomes prepared by reverse 
phase evaporation method in both 4 °C and 37 °C. The results from dynamic light 
scattering are shown below in Table 5.1 and Table 5.2. 
SAA loading was calculated by HPLC with the standard curve shown in Figure 
5.2.  The liposomes were diluted 50 times and prepared for HPLC analysis.  The 
SAA loading in the liposomes was calculated to be 9.3 mg/mL.    
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Time (day) 
4 °C 37 °C 
Zeta average size PDI Zeta average size PDI 
0 233.9 0.17 233.9 0.17 
1 264.3 0.22 246.77 0.21 
3 260.57 0.25 222.03 0.15 
10 264.83 0.26 221.85 0.10 
23 259.47 0.24 259.50 0.11 
  
Table 5.1 Colloidal stability of liposomes prepared by the thin film hydration method.  
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Time (day) 
4 °C 37 °C 
Zeta average size PDI Zeta average size PDI 
0 233.9 0.17 233.9 0.17 
1 356.27 0.47 356.27 0.47 
3 394.43 0.57 394.43 0.57 
10 457.03 0.53 457.03 0.53 
23 438.67 0.57 438.67 0.57 
 
Table 5.2 Colloidal stability of liposomes prepared by reverse phase evaporation 
method. 
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Figure 5.2 SAA standard curve determined by HPLC. 
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5.3.2 Creation of local extracorporeal vascular circuit (LEVC) 
LEVC was successfully created in mouse hind limb. Figure 5.3 A shows the 
isolation of femoral artery and vein. After ligation of the femoral artery and vein for 
3 hours, ischemic environment was created.  Figure 5.3 B shows the catheteriza-
tion of femoral artery and vein after 3 hours of ischemia.  Figure 5.3 C shows the 
closure of femoral artery and vein with 12-0 suture.  After skin closure, the mouse 
was maintained on the heating pad until recovered from anesthesia.   
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Figure 5.3  Creation of local extracorporeal vascular circuit (LEVC).  A. Isolation of 
femoral vein and artery.  B. Catheterization of femoral vein and artery.  C. Vessel 
closure by suturing two stitches on femoral vein and artery 
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5.3.3 Biodistribution and retention of liposomes after systemic or LEVC administra-
tion in ischemia-reperfusion injured mice 
Liposomes were administrated through i.v. injection or LEVC after ischemia.  1 
hour after the reperfusion, LEVC group showed higher accumulation of the lipo-
somes in ischemic limb comparing to i.v. injection group.  The majority of signal 
was detected in urine in the i.v. injected mice. Liposomes retained at the ischemic 
limb in LEVC group for more than 12 days while 2 days in i.v. injected group as 
shown in Figure 5.4.  1 day after drug administration, major organs and hind limbs 
were collected after perfusion.  From Figure 5.5, the liposomes administrated 
through tail vein were accumulated more in liver and spleen.  In LEVC group, most 
of the liposomes were retained at ischemic limb.  The organs showed very low 
signal intensity comparing to limb.  The optical imaging results indicate LEVC could 
increase the local drug concentration dramatically while lower systemic exposure. 
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Figure 5.4  In vivo optical imaging of mice treated with IRDye® 800CW encapsu-
lated SAA liposome. Upper panel shows the images of mouse treated via tail vein 
injection. Bottom panel shows the images of mouse treated via LEVC delivery sys-
tem. The majority of the signal detected from the IR injury leg in the LEVC group 
mice, while the majority of signal was detected in urine in the i.v. injection mice.  
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Figure 5.5 Ex vivo optical imaging of mice organs and hind limbs 1 day after treated 
IRDye® 800CW encapsulated SAA liposome. Upper panel shows the images of 
mouse organs and hind limbs treated via tail vein injection. The bottom panel 
shows the images of mouse organs and hind limbs treated via LEVC delivery sys-
tem. The LEVC delivery system can dramatically increase the therapeutic expo-
sure at the site of disease.  
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5.3.4  In situ detection of gastrocnemius muscle contractile force  
To evaluate the therapeutic efficacy of SAA loaded liposomes, gastrocnemius 
muscle was isolated, and the tetanic contraction force was recorded after stimulat-
ing the sciatic nerve.  The maximum tetanic contraction force from each group was 
summarized in Figure 5.6.  Control group, intravenous group, and LEVC group 
showed significant lower tetanic gastrocnemius contraction force (~20 g) compar-
ing to the sham group (~70 g). However, there was no significant difference be-
tween control, intravenous and LEVC group.  
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Figure 5.6  Maximum tetanic contraction force of gastrocnemius muscle in each 
group after ischemia-reperfusion and treatment. Control group, I.V. group, and 
LEVC group showed significant lower contraction force comparing to the sham 
group.  （One-way ANOVA with Tukey’s test , n=5, **** P < 0.0001）  
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5.3.5 Electrophysiological recording of endplate potentials (EPP) 
Electrical signals are usually transmitted from motor neurons to skeletal mus-
cles through the NMJ (neuromuscular junction), which can trigger skeletal muscle 
contraction.  The muscular tissue apoptosis during the ischemia might contribute 
to loss of gastrocnemius contraction as shown in Figure 5.6.  The function altera-
tion in NMJ could also induce the dysfunction of gastrocnemius muscle.  To test 
NMJ function in the gastrocnemius muscle, sciatic nerve-stimulated EPPs was rec-
orded and summarized in Figure 5.7.  Control group, intravenous group, and LEVC 
group showed significant lower EPP amplitudes comparing to sham group.  
Intravenous group showed significant higher EPP amplitude comparing to control 
group.  There was a trend that control group showed lower EPP amplitude com-
paring LEVC group (P=0.2664). 
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Figure 5.7 EPP amplitude recorded after stimulating sciatic nerve in different treat-
ment group after ischemic reperfusion.  Control group, I.V. group and LEVC group 
showed significant lower contraction force comparing to sham group. (One-way 
ANOVA with Tukey’s test , n=5, * P < 0.05, ** P < 0.01, **** P < 0.0001)  
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5.4 Discussion  
SAA encapsulated liposomes were successfully prepared and characterized.  
Hind limb ischemia was created by femoral artery and vein ligation. Formulated 
liposomes were administrated through tail vein injection or LEVC local circulation.  
The dose for LEVC group was 10 times higher than systemic administered group.  
Optical imaging results showed superior retention of the liposomes in ischemic 
limb with low distribution in major organs.  The liposomes signal at the ischemic 
limb declines, but can be detected for more than 12 days in LEVC group while 2 
days in tail vein group.  These results proved our hypothesis that the drug distrib-
utes more to the injury area while lower the systemic exposure to other organs like 
liver, spleen, and kidney in the LEVC treated group.  To test the therapeutic out-
come, we tested the tetanic gastrocnemius muscle contraction force after stimu-
lating the sciatic nerve.  It didn’t show significant improvement in the LEVC treated 
group comparing to no treatment control and sham group.  With the EPP amplitude 
recorded after sciatic nerve stimulation, no significant difference was observed be-
tween control and LEVC group. Significant higher endplate potential was 
monitored in I.V. group comparing to no treatment control.  It indicates that lipo-
somes formulation preserved the neuromuscular junction function after ischemia 
reperfusion injury.  Although the liposomes accumulated more in the ischemic limb 
in LEVC group, the therapeutic efficacy was not improved.  The main reason is the 
trauma created during LEVC surgery impairs the gastrocnemius muscle function.  
With the size of mouse, LEVC surgery might be a big burden to the mouse.  If 
translating LEVC to bigger animal or human, LEVC surgery could be done in a 
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minimal invasive way.  This also raises a judgment that the physician needs to 
make clinically regarding to the severity of the disease and location of the disease.  
A careful calculation of risk/benefit ratio would be essential in the selection of dis-
ease areas and patient candidates for this treatment option.  LEVC would benefit 
immensely or even provide cures to those conditions that are suitable for drug 
treatment but have not been successfully treated due to the limited drug accessi-
bility or toxicity. 
5.5 Conclusion  
 In this chapter, we proposed a new concept which delivers therapeutic agent 
locally by creating a local extracorporeal vasculature circuit using mouse hind limb 
ischemia-reperfusion injury model.  By optical imaging based biodistribution study, 
we have shown that LEVC-based drug delivery may achieve increased retention 
and more distribution of the therapeutic agent to the injured limb.  The large animal 
model might be needed to show better therapeutic efficacy by offsetting LEVC sur-
gery induced trauma. 
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CHAPTER 6.  SUMMARY 
 Brain edema is the main complication caused by traumatic brain injury. 
Brain edema is not able to be detected by traditional palpation. Micro Magnetic 
Resonance Elastography was used to detect edema at other locations of body 
clinically by measuring the stiffness of soft tissue by generating shear waves in 
tissue. Previous work has shown the stiffness change after brain injury however, it 
has not been proved to correlate with brain edema after traumatic brain injury. The 
work in second chapter focused on the edema formation pattern and severity after 
traumatic brain injury.  We found the edema pattern after brain injury correlates to 
the stiffness change pattern found in micro MRE scanning.  After this, I have been 
focusing on the treatment of traumatic brain injury and other chronic inflammatory 
diseases.  Our laboratory has developed HPMA macromolecular conjugates to de-
liver various drug payload for better treatment of the inflammatory diseases.  The 
achievement we obtained proved our hypothesis that the macromolecular prodrug 
delivery system could target to the inflammatory site in the various pathological 
situation and may improve the therapeutic outcome.  In my Ph.D. program of study, 
I focused on the investigation of the HPMA copolymer delivering dexamethasone 
(P-Dex) and tofacitinib (P-Tofa) to two different inflammatory diseases which are 
traumatic brain injury and inflammatory bowel disease.  Two different conjugates 
with different drug payload were synthesized for this comprehensive investigation.  
The labeled conjugates showed their targeting property to the inflammatory site in 
optical imaging based biodistribution study in both traumatic brain injury and in-
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flammatory bowel disease mouse model.  They showed superior therapeutic effi-
cacy with limited toxicity.  P-Dex prevented the mice death from TBI significantly 
comparing to free dexamethasone treatment.  P-Dex treatment also prevented the 
bone loss found in TBI mice after 6 weeks.  The micro architecture of trabecular 
bone in secondary spongiosa of proximal tibia was preserved by P-Dex.  We also 
validated the therapeutic efficacy of P-Tofa in the treatment of DSS-induced 
chronic ulcerative colitis mouse model.  A single systemic administration of P-Tofa 
provided superior and sustained therapeutic efficacy comparing to dose equivalent 
daily Tofa treatment.  To further improve the targeting property while limiting the 
systemic toxicity, we proposed to create a local drug delivery method in extreme 
conditions such as severe infection, inoperable cancer, cancer metastasis, organ 
failure, and prolonged ischemic condition.  We successfully created the Local Ex-
tracorporeal Vascular Circuit on mouse limb to treat the hind limb ischemia.  The 
liposomes prepared for the treatment accumulated predominantly at the hind limb 
administrated through LEVC system.  Other organs showed very weak signal in-
tensity from optical imaging.  We failed to show positive therapeutic effects due to 
the trauma caused by LEVC is significant to the mouse. 
6.2 Future plan 
 Overall, this project broadened the application of HPMA based copolymer de-
livering various therapeutic agents to treat different inflammatory diseases.  We 
proved the concept of LEVC system which could deliver a superior high concen-
tration of therapeutic agents in extreme conditions with very low systemic exposure.  
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Future studies focusing on non-invasive local treatment might provide better ther-
apeutics with limited toxicity. 
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